Additive for protein or cells

Abstract

To provide an excellent additive for protein or cells.SOLUTION: An additive for protein or cells contains an amino acid-based polymer (A) having an amino acid residue-containing structural unit. The amino acid-based polymer (A) has a mass average molecular weight of 2,000 or more. The amount of unfreezable water measured in aqueous solution with the concentration of the amino acid-based polymer (A) being 20.0 w / v% 200 mg or more for 1 g of the polymer (A).SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to an additive for proteins or cells. [Background technology]

[0002] In recent years, industrial mass production of useful physiologically active substances (hormones, neurotransmitters, cytokines, vitamins and minerals, enzymes, nucleic acids, etc.), including monoclonal antibodies, has become increasingly common through mass cultivation of animal cells. In such cases, animal serum such as fetal bovine serum (FBS) is frequently used as a growth factor. Specifically, a culture medium in which about 10-20% by volume of animal serum such as fetal bovine serum (FBS) is added to a synthetic basal medium such as RPM11640, Eagle's MEM, or Ham's F12 is generally used.

[0003] However, animal sera such as fetal bovine serum (FBS) are limited in supply and generally expensive. This leads to an increase in the cost of culture media and an increase in the manufacturing cost of physiologically active substances. It also leads to the drawback that it is difficult to isolate the desired physiologically active substances from culture solutions containing serum-derived proteins. Furthermore, there is variation in quality between lots of serum. Therefore, it is necessary to thoroughly check the lot before using serum and select a usable serum, but this selection of serum requires a lot of effort. In addition, animal-derived serum has problems related to prion-related diseases such as mad cow disease, bovine spongiform encephalopathy, infectious spongiform encephalopathy, and even Creutzfeldt-Jakob disease, and since animal-derived serum cannot be sterilized by autoclaving, it may be contaminated with viruses or mycoplasma, which poses risks (safety issues) such as infectious diseases.

[0004] In order to solve the above problems, serum-free media have been investigated. For example, Patent Document 1 discloses that adding glycylglycine to a medium can cause animal cells to produce useful substances at high concentrations. Patent Document 2 discloses that when cells are cultured in a medium containing a polymer having a phospholipid-like structure, a physiologically active substance can be produced efficiently. Patent Document 3 discloses that a medium containing a hydrophobic D-amino acid promotes cell growth and increases the production of useful substances. However, most of the media containing such serum substitutes are not sufficient in terms of proliferation, survival, and antibody productivity of antibody-producing cells, compared with serum-containing media. Furthermore, most of the serum substitutes are derived from natural products, have supply restrictions, and are generally expensive. For these reasons, there is a need for the development of serum substitutes to replace fetal bovine serum (FBS).

[0005] Furthermore, with the recent development of biotechnology, securing genetic resources of living organisms has become important, and it has become necessary to permanently preserve cells and tissues of animals, plants, microorganisms, etc. Conventionally, when freezing and preserving animal cells, the following problems have been raised: In order to preserve many animal cells in good condition for a long period of time, they must be frozen at -130°C or below (below the vitrification temperature of water), and if the temperature rises, the cells will lose their function. For this reason, when transporting frozen cells, a form of cryogenic transportation using liquid nitrogen as a cooling means is adopted, but this has the problem of being expensive. Therefore, there is a need to develop a cell preservation solution that allows long-term transportation at low cost without losing the cells' function. For example, Patent Document 4 describes that mesenchymal stem cells can be frozen using a cryopreservation solution containing hydroxyethyl starch (HES) and dimethyl sulfoxide (DMSO), and that even if these frozen cells are stored at -80°C, they can maintain their survival and proliferation ability after thawing. By using this method, it is possible to transport mesenchymal stem cells on dry ice without losing their function. However, this cryoprotection solution contains serum Albumin or serum was often included. The components of serum have not yet been fully elucidated, and there is also a risk of the presence of pathogenic viruses that induce some mutations in animal cells during cryopreservation. In addition, in June 2013, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee announced a recommendation to suspend the marketing approval of HES preparations, based on the results of overseas clinical trials that showed safety issues with the preparations. Therefore, there was a demand for a cryopreservation solution that could be transported for long periods of time without using serum.

[0006] Low molecular weight solvents including DMSO, glycerin, ethylene glycol (EG), and propylene glycol (PG) are used for cell cryopreservation. These are thought to be effective in preventing ice crystals from forming inside cells when they are frozen, and are cell membrane permeable, slowing down the rate of ice crystallization and inhibiting ice crystal formation by promoting cell dehydration. However, when DMSO is included, processing such as washing the thawed cells is required to reduce cytotoxicity (Patent Document 7). In particular, it has been reported that the use of DMSO reduces the gene expression level of Oct-4, a pluripotent stem cell. (Non-Patent Document 2)

[0007] In recent years, attention has been focused on culturing cells in three dimensions to form cell spheroids (cell aggregates cultured in three dimensions) of various shapes. It is known that three-dimensionally cultured spheroids exert different functions from cells cultured on a flat surface. Cell spheroids are in a cellular environment closer to that of a living body, and are thought to be able to exert cellular functions in the living body, so analysis using cell spheroids and application technology of spheroids are being actively researched. In spheroids, cells are connected by gap junctions, and it is difficult for cryoprotectants to diffuse uniformly to the cells inside, and there is a time difference in freezing between the inside and the periphery of the spheroid. This causes twisting and destruction of intercellular adhesion, and there are concerns about a decrease in the freezing efficiency of spheroids due to the intertwining of complex factors compared to when freezing single cells. In fact, it has been reported that when human ES cell or iPS cell colonies (cell aggregates cultured in two dimensions) are dispersed in a cryoprotectant containing 10 v / v% DMSO and slowly frozen under the same conditions as single cells, the survival rate after thawing is very low (Non-Patent Document 2).

[0008] In addition, in Patent Document 7, a polymer in which the amine group of polylysine, a polyamino acid, is modified with succinic anhydride is used as a cell cryopreservation agent in combination with propylene glycol, and the survival efficiency after thawing is shown. Furthermore, it has been reported that the undifferentiated state of human mesenchymal stem cells and human adipose-derived stem cells is maintained. This is thought to be due to the fact that polylysine has affinity for cell membranes due to the amine groups and exerts a protective effect on cells, and in addition, the negative charge of the carboxyl group reduces the affinity with cell membranes, so that it exhibits a very weak interaction with cell membranes and exerts a cryoprotection effect by protecting cell membranes without causing toxicity. However, there is a problem that the synthesis process of polylysine in Patent Document 7 is complicated and expensive from the viewpoint of industrialization.

[0009] Furthermore, among stem cells, ES cells and iPS cells easily deviate from the undifferentiated state and differentiate due to medium components, stress, etc. There is concern that DMSO contained in the cryopreservation solution may also act as such a differentiation factor. Although no comparative data not containing DMSO has been disclosed, for example, a decrease in the expression of undifferentiated marker genes after cryopreservation has been reported in a case where 10 v / v% DMSO was used as a cryopreservation solution (Non-Patent Document 2). Therefore, it is also desirable to develop a low-toxicity cell preservation solution by reducing the amount of low-molecular-weight solvents.

[0010] As a method for freezing such 3D cultured cell aggregates, a vitrification method has been developed that improves on the vitrification method for mouse fertilized eggs, which are larger than somatic cells (a method in which the inside of the cell is dehydrated and replaced using EG 15 v / v%, DMSO 10 v / v%, and sucrose 0.5 M, and the entire cell is vitrified and fixed by quickly lowering the temperature to liquid nitrogen) (Non-Patent Document 3). However, in this method, the vitrification liquid is a mixture of DMSO / acetamide / PG = 2 / 1 / 3 [M]. It was a very concentrated solution with high osmotic pressure. Therefore, it was necessary to suspend the cells and immerse them in liquid nitrogen for 15 to 30 seconds, and most of the cells died if left for even one minute. In addition, there is a risk that the vitrified water will recrystallize when thawed, so thawing must be done as quickly as possible, making the process complicated. Furthermore, the transport containers (metal containers with liquid nitrogen trapped in their pores) are very large, which creates the problem of high transport costs. Furthermore, while the vitrification method made it possible to freeze individual colonies or fertilized eggs, it was not suitable for freezing large amounts of cell aggregates. Therefore, there is a need for the development of a simpler, more efficient freezing method.

[0011] On the other hand, in the past, many proposals have been made to use a combination of sugars and low molecular weight solvents in cell cryopreservation solutions. For example, a method for cryopreserving plant cells using a cryoprotectant solution consisting of an aqueous solution containing 20-70 w / v% glycerin, 10-70 w / v% sucrose, and optionally 5-10 w / v% polyhydric alcohol (Patent Document 5), a method for cryopreserving stem cells using a cryopreservation solution containing EG, D-MEM, albumin, and sugars in combination (Patent Document 6), etc. have been reported. However, the methods described in Patent Documents 5 and 6 can only be applied to specific cells such as plants or stem cells, and have not been able to solve all of the above problems.

[0012] Furthermore, physiologically active substances such as monoclonal antibodies are proteins, and their stability is an issue. Proteins maintain their higher-order structure through weak non-covalent polar interactions within the polypeptide chain, such as van der Waals interactions, hydrogen bonds, and electrostatic interactions, and various functions are expressed through such higher-order structure. These bonds are altered by various external factors (temperature, pH, salt concentration, concentration of the protein itself, surfactants, denaturants, divalent metals, coexistence of proteases), and in some cases the protein structure is destroyed and the original function is lost. Therefore, protein stability can be rephrased as the ability to maintain a functional higher-order structure.

[0013] For these reasons, proteins need to be stabilized in aqueous solution, and optimization of storage conditions, such as storing them in a buffer solution at a constant specified temperature, and the use of stabilizers (other proteins such as albumin, polyhydric alcohols such as glycerol, polyethylene glycol, and sucrose, amino acids such as glutamic acid and lysine, reducing agents such as glutathione and dithiothreitol, metal chelating agents such as EDTA, organic acid salts such as citric acid, heavy metal salts, substrates, and coenzymes) alone or in combination have been investigated (Non-Patent Document 4).

[0014] In particular, as stabilizers for synthetic compounds, for example, Patent Document 8 discloses a method of using a polymer having a phosphorylcholine group, Patent Document 9 discloses a polymeric compound having a polyethylene glycol moiety, Patent Document 3 discloses a low molecular weight amine oxide compound, and Patent Documents 11 and 12 discloses a method of using an amphoteric ionic polymer. However, depending on the type of protein, these methods may not provide a satisfactory retention rate or stability period, and further improvements are required.

[0015] In the field of biochemical analysis, the method of detecting and visualizing DNA and proteins by utilizing specific adsorption due to antigen-antibody reactions is widely known as the Southern blotting method, Western blotting method, ELISA method, immunostaining method, etc. Antibodies also cause non-specific adsorption reactions with proteins other than the target protein. In order to prevent such non-specific adsorption, a pretreatment is performed in which the surface to be detected or measured is covered with a blocking agent that prevents non-specific adsorption but does not interfere with specific adsorption.

[0016] Known blocking agents include proteins derived from living organisms, such as normal serum, bovine serum albumin, gelatin, and skim milk (Patent Document 13, Non-Patent Document 5). In addition, examples of blocking agents include a surfactant called TWEEN (registered trademark) 20, Copolymers of hydroxyalkylcellulose, polyvinyl alcohol, and (meth)acryloylmorpholine with other monomers are also known (Patent Documents 14, 15, and 16). Additionally, blocking agents using copolymers having phosphorylcholine groups in the side chains have also been investigated (Patent Document 17, Non-Patent Document 6).

[0017] However, proteins derived from living organisms as disclosed in Patent Document 13 and Non-Patent Document 5 have a strong blocking effect, but have a potential problem that their performance is prone to variation, such as an inhibitory effect on antigen-antibody reactions. Meanwhile, a blocking agent is required to not hinder the coloring when a staining agent specifically adsorbs to a protein that is a target of staining and develops color, and to cover proteins other than the target so that the staining agent does not adsorb to the proteins other than the target and do not develop color. However, the surfactants and the like disclosed in Patent Documents 14 to 16 have problems such as hindering coloring due to specific adsorption of the staining agent to the target protein, or not being able to sufficiently cover proteins other than the target, causing the staining agent to adsorb to the proteins other than the target and develop color. Furthermore, the copolymer disclosed in Patent Document 17 has a problem in productivity, such as the need for multiple reactions and the associated purification during the synthesis of the raw material monomer. [Prior art documents] [Patent documents]

[0018] [Patent Document 1] Japanese Patent Application Publication No. 7-23780 [Patent Document 2] Japanese Patent Application Publication No. 4-304882 [Patent Document 3] JP 2015-027265 A [Patent Document 4] Patent Publication No. 2020-39326 [Patent Document 5] Patent Publication No. 6-292564 [Patent Document 6] Patent Publication 2019-154329 [Patent Document 7] Patent Publication No. 2011-30557 [Patent Document 8] Japanese Patent Application Publication No. 10-45794 [Patent Document 9] Japanese Patent Application Publication No. 10-237094 [Patent Document 10] Special Publication No. 2007-509164 [Patent Document 11] International Publication No. 2019-131757 [Patent Document 12] Patent Publication No. 2021-3020 [Patent Document 13] International Publication No. 2016 / 052690 [Patent Document 14] JP 2004-219111 A [Patent Document 15] Japanese Patent Application Publication No. 04-019561 [Patent Document 16] JP 2008-209114 A [Patent Document 17] Japanese Patent Application Publication No. 7-083923 [Non-patent literature]

[0019] [Non-Patent Document 1] Katkov et al., Cryobiology, 2006,53(2).194-205 [Non-Patent Document 2] Nishigaki T, Teramura Y, Suemori H, Iwata H, Cryobiology 2010;6:159-164 [Non-Patent Document 3] Fujioka T, Yasuchika K, Nakamura Y, Nakatsuji N, Suemori H, Int. J. Dev. Biol. 2004, 48:1149-1154 [Non-Patent Document 4] New Biochemistry Experiment Course 1 Protein I Separation, Purification, and Properties Chapter 16 [Non-Patent Document 5] "Watanabe and Nakane, Enzyme Immunosorbent Assay" published by Gakusai Kikaku Co., Ltd., 2002 [Non-Patent Document 6] Polymer Journal Vol. 35 No. 7 423(1978) Summary of the Invention [Problem to be solved by the invention]

[0020] An object of the present invention is to provide an excellent additive.

[0021] Another object of the present invention is to provide a protein stabilizer that allows stable storage of a protein without impairing the function of the protein, and a method for stabilizing a protein using the protein stabilizer.

[0022] Another object of the present invention is to provide a blocking agent that exhibits an excellent blocking effect in immunostaining and immunoassay utilizing an antigen-antibody reaction, preventing non-specific reactions and not interfering with the assay, and that improves detection sensitivity and is less susceptible to performance variations, and also to provide an immunostaining method and an immunoassay method using said blocking agent.

[0023] Another object of the present invention is to provide a cell culture medium additive suitable for enhancing the production of a physiologically active substance during animal cell culture without using serum. Furthermore, the present invention also provides a method for producing a physiologically active substance using a medium containing the cell culture medium additive.

[0024] The present invention also provides a cryopreservation solution that does not use serum, has low cytotoxicity, and can also be used to freeze cell aggregates, as well as a simple and highly efficient method for cryopreserving cells. [Means for solving the problem]

[0025] [1] An additive for proteins or cells, comprising an amino acid polymer (A) having an amino acid residue-containing structural unit. [2] The additive according to claim 1, wherein the amino acid polymer (A) has a mass average molecular weight of 2,000 or more. [3] The additive according to [1] or [2], wherein the amount of nonfreezing water measured in an aqueous solution having an amino acid polymer (A) concentration of 20.0 w / v % is 200 mg or more per 1 g of the polymer. [4] The additive according to [1] or [2], wherein the amino acid polymer (A) has at least any one of structural units represented by the following general formulas (1) to (3): [ka] ...General formula (1) [ka] ...General formula (2) [ka] ...General formula (3) In the general formulas (1) to (3), A represents an amino acid residue, and X and Y each independently represent O or or NH, R1 is an alkylene group, and R2 is an alkylene group, an alkylene group in which one or more hydrogen atoms are substituted with hydroxyl groups, a phenylene group, an ester group, an ether group, a urethane bond, an amide bond, or a nonionic divalent group consisting of a combination of these. [5] The additive according to [1] or [2], wherein the amino acid polymer (A) contains 30 to 100 mass% of at least any one of the structural units represented by the general formulas (1) to (3), relative to 100 mass% in total of the structural units constituting the amino acid polymer (A). [6] The additive according to [1] or [2], which is a protein stabilizer or a blocking agent. [7] The additive according to [6], wherein the concentration of the amino acid polymer (A) is 0.01 to 30.0 w / v %. [8] A method for stabilizing a protein, comprising allowing the protein stabilizing agent according to [6] to coexist with the protein. [9] An immunoassay method comprising the step of treating a carrier containing an antigen or antibody with the blocking agent according to [6].

[10] The immunoassay method described in [9], wherein the carrier is a latex particle.

[11] A carrier containing an antigen or antibody against a target substance, the carrier being partially or completely coated with the blocking agent according to [6].

[12] A kit for immunoassay comprising the carrier described in [7].

[13] A cell culture medium comprising the additive according to [1] or [2].

[14] The cell medium according to

[13] , wherein the concentration of the amino acid polymer (A) in the medium is 0.001 to 1 mass %.

[15] A method for producing a spheroid or a physiologically active substance, comprising culturing cells in the cell culture medium according to

[13] .

[16] The additive according to [1] or [2], which is a cell cryoprotectant.

[17] A cell cryopreservation solution comprising the cell cryoprotectant according to

[16] .

[18] The cell cryopreservation solution according to

[17] , further comprising a low molecular weight solvent and having an osmotic pressure of 500 to 2500 mOsm / kg.

[19] The cell cryopreservation solution according to

[17] , wherein the concentration of the amino acid polymer (A) is 0.1 to 30.0 w / v %.

[20] The cell cryopreservation solution described in

[17] , wherein the low molecular weight solvent is at least one selected from the group consisting of dimethyl sulfoxide, propylene glycol, ethylene glycol and glycerin, and the content of the low molecular weight solvent is 5.0 w / v% or less.

[21] A method for freezing cells, comprising the steps of mixing the cell cryopreservation solution according to

[17] with cells, and freezing the mixture of the cell cryopreservation solution and the cells.

[22] A spheroid frozen using the cell freezing medium described in

[17] .

[23] An organoid frozen using the cell freezing medium described in

[17] . Effect of the Invention

[0026] According to the present invention, an excellent additive can be provided.

[0027] The cell medium additive using the additive of the present invention can increase the production amount of a physiologically active substance when the additive is added to a cell medium and the obtained medium is used to culture cells capable of producing the physiologically active substance. In particular, the productivity of a physiologically active substance per amount of DNA can be increased. In addition, the addition of the cell medium additive of the present invention can promote the productivity of a desired physiologically active substance, which is also useful in terms of reducing production costs and labor. For example, in the case of antibodies, it can greatly contribute to the mass supply of biopharmaceuticals such as antibody drugs.

[0028] The cell cryoprotectant utilizing the additive of the present invention can provide a cryopreservation solution that has low cytotoxicity and can be used to freeze cell aggregates without using animal-derived components such as serum, as well as a simple and highly efficient method for cryopreserving cells.

[0029] The protein stabilizer utilizing the additive of the present invention can provide a protein stabilizer that allows stable storage without impairing the function of the protein by using an amino acid polymer having an amino acid residue-containing structural unit and a mass-average molecular weight of not less than 2,000. Furthermore, by allowing the protein stabilizer to coexist with a protein, a method for stabilizing a protein can be provided that allows stable storage without impairing the function of the protein.

[0030] In addition, the blocking agent using the additive of the present invention can block non-specific reactions in immunoassays using antigen-antibody reactions in a wider range of measurement targets than conventional methods. That is, even in cases where the measurement of a target substance is inhibited by conventional blocking agents or methods, blocking using an amino acid polymer having an amino acid residue-containing structural unit and a mass average molecular weight of 2,000 or more can provide a sufficient blocking effect, and such target measurement can be performed without being inhibited. Furthermore, the amino acid polymer can stably exhibit its function without the risk of BSE associated with the use of BSA, a bovine component, and without the risk of performance variation due to lots specific to biological origin. By using this blocking agent, it is possible to perform biochemical analysis using antigen-antibody reactions such as Western blotting, immunohistochemical staining, ELISA, and immunochromatography with good sensitivity. For example, in immunohistochemical staining, the blocking agent for biochemical analysis of the present invention is brought into contact with a pathological tissue fixed on the surface of a substrate, and then the antigen in the pathological tissue is adsorbed with a staining antibody to detect the antigen. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0031] The additive of the present invention is characterized by containing an amino acid polymer (A) having an amino acid residue-containing structural unit.

[0032] <Amino acid polymer (A)>

[0033] In the present invention, the amino acid polymer (A) is a polymer having an amino acid residue-containing structural unit, and is preferably a polymer of a monomer composition containing a monomer having an amino acid residue structure. The monomer having an amino acid residue structure is preferably an ethylenically unsaturated monomer having an ethylenically unsaturated group introduced via an amino group, a carboxy group, a hydroxy group, or other reactive group of an amino acid or an amino acid derivative.

[0034] The amino acids may be D- or L-amino acids, or mixtures thereof such as DL- or racemic forms. L-amino acids are particularly preferred because they are amino acids that constitute living organisms. Among these, the amino acids that constitute living organisms, valine, leucine, isoleucine, alanine, arginine, glutamine, lysine, aspartic acid, glutamic acid, proline, cysteine, etc., are particularly preferred. More preferably, it is one or more selected from the group consisting of threonine, methionine, histidine, phenylalanine, tyrosine, tryptophan, asparagine, glycine, and serine. The amino acid derivative is one in which one hydrogen atom of the amino group, carboxyl group, or other functional group of the amino acid is replaced with another functional group, and an ethylenically unsaturated group can be introduced through these substituents. The substituent is not particularly limited, but an alkyl group having an amino group, a carboxyl group, a hydroxyl group, or the like is preferable. The amino acids and amino acid derivatives may be protected, but are preferably ultimately deprotected.

[0035] The amount of nonfreezing water measured in an aqueous solution containing 20 w / v% of the amino acid polymer (A) is preferably 200 mg or more, more preferably 250 mg or more, per 1 g of the amino acid polymer. Nonfreezing water is water that does not freeze even at temperatures below -100°C, and the greater the amount of nonfreezing water, the more the cells can be prevented from being physically damaged by ice crystal growth when frozen. By containing a certain amount or more of nonfreezing water, a stable hydration state can be maintained outside the cell membrane of the cells, the high penetration rate of low molecular weight solvents can be controlled, and the cryopreservation properties of the cells can be improved.

[0036] <Mass average molecular weight (Mw)> The weight average molecular weight of the amino acid polymer (A) is preferably 2,000 or more, more preferably 5,000 to 100,000. By having a weight average molecular weight of 2,000 or more, when used as a protein stabilizer and blocking agent, non-specific adsorption to targets other than the protein target can be suppressed. In addition, when used as a cell additive, uptake into cells can be suppressed. By having a weight average molecular weight of 100,000 or less, it can be made into an aqueous solution, and the solubility in a medium or the like is improved. Furthermore, the thickening effect can be reduced, defects such as gelation can be prevented, and handling such as pipetting can be facilitated. The weight average molecular weight of the amino acid polymer (A) is a value measured by gel permeation chromatography (GPC) in terms of standard polyethylene glycol.

[0037] The amino acid polymer (A) preferably has at least one of the structural units represented by the general formulae (1) to (3) in the side chain as an amino acid residue-containing structural unit. The structural units are preferably contained in a total of 30 to 100% by mass, more preferably 40 to 100% by mass, and more preferably 50 to 100% by mass, relative to 100% by mass of the total structural units constituting the amino acid polymer. By being in the above range, interaction with membrane proteins and phospholipids on the cell surface becomes easy, and the performance of the cells, including the antibody productivity, can be further improved. In addition, the cryopreservability of the cells is further improved. Furthermore, when coexisting with a protein, suitable water solubility is expressed, polarity is controlled, the surrounding environment can be appropriately controlled, and protein stability is improved. [ka] ...General formula (1) [ka] ...General formula (2) [ka] ...General formula (3)

[0038] In formulas (1) to (3), A represents an amino acid residue, X and Y each independently represent O or NH, R1 represents an alkylene group, R2 represents an alkylene group, an alkylene group in which one or more hydrogen atoms are substituted with hydroxyl groups, a phenylene group, an ester group, an ether group, a urethane bond, an amide bond, or a nonionic divalent group composed of a combination thereof.

[0039] The amino acid residue is not particularly limited as long as it has a structure derived from the above-mentioned amino acids or amino acid derivatives, and examples thereof include monovalent groups obtained by removing one hydrogen atom from the amino group, carboxyl group, or other functional group of amino acids and amino acid derivatives.

[0040] The alkylene group of R1 includes linear, branched, or cyclic alkylene groups, such as methylene, ethylene, propylene, butylene, trimethylene, tetramethylene, hexamethylene, octamethylene, 1,2-cyclohexene, 1,3-cyclohexene, 1,4-cyclohexene, and 2-methylpropene groups. An alkylene group having 1 to 6 carbon atoms is preferred. The alkylene group for R2 includes the same as those for R1, and also includes alkylene groups in which one or more hydrogen atoms have been replaced with a hydroxyl group. The phenylene group of R2 is an ortho-phenylene group, a meta-phenylene group, a para-phenylene group, Examples of such groups include aryl groups. Examples of the ester group for R2 include an ester group, a thioester group, a phosphate group, a sulfate group, a nitrate group, and a carbonate group. The ether group of R2 may be an ether bond or a polyether group, such as an ethylene glycol group, a propylene glycol group, or a tetramethylene glycol group, and may have a structure in which two or more of these groups are connected together. In addition to the above, R2 may be a urethane bond or an amide bond, or may be composed of a combination of two or more of these substituents.

[0041] The amino acid polymer is preferably water-soluble, and the water solubility can be appropriately adjusted depending on the amino acid monomer and other monomers used. In the present invention, water solubility means that the resin can be completely dissolved in water without separation or precipitation after 1 g of the resin is added to 99 g of ion-exchanged water at 25° C., stirred, and left at 25° C. for 24 hours.

[0042] The structural unit represented by the general formula (1) or (3) is preferred because the water solubility of the amino acid polymer can be easily adjusted. From the viewpoint of the water solubility of the amino acid polymer (A), the structural unit represented by the general formula (2) is preferably 75% by mass or less, more preferably 50% by mass or less, based on 100% by mass of the total of the structural units constituting the amino acid polymer (A).

[0043] The amino acid polymer (A) can also be obtained by copolymerizing at least one of the monomers (a1) to (a3) ​​having an amino acid residue structure represented by the following general formulas (4) to (6) with other monomers as required. In this specification, such a monomer having one ethylenically unsaturated group and an amino acid residue structure in one molecule is referred to as an amino acid monomer. Monomer (a1) [ka] ...General formula (4) Monomer (a2) [ka] ...General formula (5) Monomer (a3) [ka] ...General formula (6)

[0044] In general formulas (4) to (6), A represents an amino acid residue, X and Y each independently represent O or NH, R1 represents an alkylene group, R2 represents an alkylene group, an alkylene group in which one or more hydrogen atoms are substituted with hydroxyl groups, a phenylene group, an ester group, an ether group, a urethane bond, an amide bond, or a nonionic divalent group composed of a combination of these, and R3 represents H or CH3.

[0045] The amino acid monomer (a1) can be obtained, for example, by reacting an amino acid or an amino acid derivative with a compound having an alkyl halide and a (meth)acryloyl group in one molecule. A preferred method for producing such an amino acid monomer (a1) is, for example, to synthesize the monomer by dropping (meth)acryloyl chloride into an aqueous solution containing an amino acid or an amino acid derivative under ice cooling. When using an amino acid protected by a protecting group, it is preferable to deprotect the amino acid after the above reaction.

[0046] The amino acid monomer (a2) can be obtained, for example, by reacting an amino acid or an amino acid derivative with an ethylenically unsaturated monomer having a styrene skeleton and a halogenated alkyl group in one molecule. A preferred method for producing such an amino acid monomer (a2) is, for example, to dissolve a protected amino acid and, if necessary, a basic compound in a protic solvent in advance, and then add and react an ethylenically unsaturated monomer having a styrene skeleton and a halogenated alkyl group in one molecule to synthesize a protected amino acid monomer as a precursor. The protected amino acid monomer is preferably deprotected to obtain an amino acid monomer. Alternatively, proline can be used instead of the protected amino acid to obtain the amino acid monomer (a2). Examples of ethylenically unsaturated monomers having a styrene skeleton and a halogenated alkyl group in one molecule include chloromethylstyrene, chloroethylstyrene, chloropropylstyrene, chlorobutylstyrene, bromomethylstyrene, bromoethylstyrene, bromopropylstyrene, bromobutylstyrene, etc. These may contain structural isomers such as ortho-, meta-, and para-isomers.

[0047] The amino acid monomer (a3) ​​can be obtained, for example, by subjecting an amino group of an amino acid to a Michael addition reaction with an acryloyl group of a bifunctional ethylenically unsaturated monomer having an acryloyl group.

[0048] As a bifunctional ethylenically unsaturated monomer, there is a monomer having two acryloyl groups in one molecule. and ethylenically unsaturated monomers having one acryloyl group and one methacryloyl group in one molecule. Examples of bifunctional ethylenically unsaturated monomers having two acryloyl groups in one molecule include ethylene glycol diacrylate, neopentyl glycol diacrylate, 1,6-hexanediol diacrylate, 1,9-nonanediol diacrylate, triethylene glycol diacrylate, polyethylene glycol diacrylate (Kyoeisha, Light Acrylate 4EG-A, 9EG-A, 14EG-A), 3-methyl-1,5-pentanediol diacrylate, polytetramethylene glycol diacrylate, dimethyloltricyclodecane diacrylate, 2-butyl-2-ethyl-1,3-propanediol diacrylate, and the like.

[0049] Examples of the ethylenically unsaturated monomer having one acryloyl group and one methacryloyl group in one molecule include a bifunctional ethylenically unsaturated monomer obtained by an esterification reaction between methacryloyl chloride and a hydroxyl group-containing acrylate, or between acryloyl chloride and a hydroxyl group-containing methacrylate; a bifunctional ethylenically unsaturated monomer obtained by a ring-opening reaction between a carboxyl group-containing acrylate and a glycidyl group-containing methacrylate, or between a carboxyl group-containing methacrylate and a glycidyl group-containing acrylate; and a bifunctional ethylenically unsaturated monomer obtained by an addition reaction between an isocyanate group-containing acrylate and a hydroxyl group-containing methacrylate, or between an isocyanate group-containing methacrylate and a hydroxyl group-containing acrylate. These difunctional ethylenically unsaturated monomers may be synthesized by reacting the above-mentioned monofunctional ethylenically unsaturated monomers in combination, or commercially available products may be used. Examples of the hydroxyl group-containing acrylate (c-1) include 2-hydroxyethyl acrylate, 2-hydroxypropyl acrylate, 4-hydroxybutyl acrylate, 2-acryloyloxyethyl 2-hydroxyethyl phthalate, polyethylene glycol monoacrylate (NOF Corp., Blenmer AE-90U, AE-200, AE-400), polypropylene glycol monoacrylate (NOF Corp., Blenmer AP-200, AP-400, AP-550, AP-800), polyethylene glycol-polypropylene glycol monoacrylate (NOF Corp., Blenmer AEP), and hydroxyethyl acrylamide. Examples of hydroxyl group-containing methacrylates (c-2) include 2-hydroxyethyl methacrylate, 2-hydroxypropyl acrylate, 2-methacryloyloxyethyl 2-hydroxyethyl phthalate, polyethylene glycol monomethacrylate (manufactured by NOF Corp., PE-90, PE-200, PE-350), polyethylene glycol monomethacrylate (Blenmer PP-1000, PP-500, PP-800), polyethylene glycol-polypropylene glycol monomethacrylate (manufactured by NOF Corp., Blenmer 50PEP-300, 70PEP-350B), and hydroxylethyl methacrylamide. Examples of the carboxyl group-containing acrylate (d-1) include acrylic acid, 2-acryloyloxyethyl succinic acid, 2-acryloyloxyethyl phthalic acid, and 2-acryloyloxyethyl hexahydrophthalic acid. Examples of the carboxyl group-containing methacrylate (d-2) include methacrylic acid, 2-methacryloyloxyethyl succinic acid, and 2-methacryloyloxyethyl hexahydrophthalic acid. Examples of the glycidyl group-containing methacrylate (e-1) include glycidyl methacrylate, etc. Examples of the glycidyl group-containing acrylate (e-2) include glycidyl acrylate, 4-hydroxybutyl acrylate glycidyl ether, etc. Examples of the isocyanate group-containing acrylate (f-1) include 2-isocyanatoethyl acrylate, etc. Examples of the isocyanate group-containing methacrylate (f-2) include 2-isocyanatoethyl methacrylate, Karenz MOI-E, manufactured by Showa Denko K.K. Examples include G.

[0050] Among the bifunctional ethylenically unsaturated monomers listed above, ethylenically unsaturated monomers having one acryloyl group and one methacryloyl group per molecule are preferred. With ethylenically unsaturated monomers having two acryloyl groups, by-products in which amino acids are added to both are also generated at the same time. Therefore, the yield of the target product in which an amino acid is added to only one of the acryloyl groups is reduced. On the other hand, with ethylenically unsaturated monomers having one acryloyl group and one methacryloyl group per molecule, the amino acid is selectively added to the acryloyl group, so that the target product in which only the methacryloyl group remains can be obtained in a higher yield.

[0051] <Monomer (b)> When obtaining an amino acid polymer, in addition to the amino acid monomers (a1) to (a3), another monomer (b) having one ethylenically unsaturated group in one molecule can be copolymerized. For example, Linear or branched, alicyclic alkyl group-containing ethylenically unsaturated monomers such as methyl (meth)acrylate, ethyl (meth)acrylate, propyl (meth)acrylate, butyl (meth)acrylate, pentyl (meth)acrylate, heptyl (meth)acrylate, 2-ethylhexyl (meth)acrylate, cyclohexyl (meth)acrylate, octyl (meth)acrylate, nonyl (meth)acrylate, decyl (meth)acrylate, undecyl (meth)acrylate, lauryl (meth)acrylate, tridecyl (meth)acrylate, tetradecyl (meth)acrylate, pentadecyl (meth)acrylate, hexadecyl (meth)acrylate, heptadecyl (meth)acrylate, stearyl (meth)acrylate, isostearyl (meth)acrylate, behenyl (meth)acrylate, and isobornyl (meth)acrylate; α-olefinic ethylenically unsaturated monomers such as 1-propylene, 1-butene, 1-pentene, 1-hexene, 1-octene, 1-nonene, and 1-decene; Aromatic ethylenically unsaturated monomers such as styrene, α-methylstyrene, o-methylstyrene, p-methylstyrene, m-methylstyrene, vinylnaphthalene, benzyl acrylate, benzyl methacrylate, phenoxyethyl acrylate, phenoxyethyl methacrylate, phenoxydiethylene glycol acrylate, phenoxydiethylene glycol methacrylate, phenoxytetraethylene glycol acrylate, phenoxytetraethylene glycol methacrylate, phenoxyhexaethylene glycol acrylate, phenoxyhexaethylene glycol methacrylate, phenyl acrylate, and phenyl methacrylate; (Meth)acrylamide, N-methoxymethyl-(meth)acrylamide, N-ethoxymethyl-(meth)acrylamide, N-propoxymethyl-(meth)acrylamide, N-butoxymethyl-(meth)acrylamide, N-pentoxymethyl-(meth)acrylamide, N,N-di(methoxymethyl)acrylamide, N-ethoxymethyl-N-methoxymethylmethacrylamide, N,N-di(ethoxymethyl)acrylamide, N-ethoxymethyl-N-propoxymethylmethacrylamide, N,N-di(propoxymethyl)acrylamide Amide group-containing ethylenically unsaturated monomers such as acrylamide, N-butoxymethyl-N-(propoxymethyl)methacrylamide, N,N-di(butoxymethyl)acrylamide, N-butoxymethyl-N-(methoxymethyl)methacrylamide, N,N-di(pentoxymethyl)acrylamide, N-methoxymethyl-N-(pentoxymethyl)methacrylamide, N,N-dimethylaminopropylacrylamide, N,N-diethylaminopropylacrylamide, N,N-dimethylacrylamide, and N,N-diethylacrylamide; Fluorinated alkyl group-containing ethylenically unsaturated monomers, such as trifluoroethyl (meth)acrylate and heptadecafluorodecyl (meth)acrylate; hydroxyl group-containing ethylenically unsaturated monomers such as 2-hydroxyethyl (meth)acrylate, 2-hydroxypropyl (meth)acrylate, 4-hydroxybutyl (meth)acrylate, glycerol mono(meth)acrylate, 4-hydroxyvinylbenzene, 1-ethynyl-1-cyclohexanol, and allyl alcohol; Examples of unsaturated monomers containing a polyoxyalkylene hydrophilic skeleton include polyethylene glycol (meth)acrylate, polypropylene glycol (meth)acrylate, polyethylene glycol polypropylene glycol (meth)acrylate, polyethylene glycol polytetramethylene glycol (meth)acrylate, polypropylene glycol polytetramethylene glycol (meth)acrylate, methoxypolyethylene glycol (meth)acrylate, and ethoxypolyethylene glycol (meth)acrylate. The other monomers (b) may be used appropriately as required within the scope of the present invention, and two or more kinds may be used in combination.

[0052] <Method for producing amino acid polymer (A)> The amino acid polymer (A) can be obtained by, for example, ordinary solution polymerization using the amino acid monomers (a1) to (a3) ​​and, if necessary, another monomer (b) having one ethylenically unsaturated group in one molecule. The following are examples of the production method. In a reaction vessel equipped with a nitrogen gas inlet tube, a condenser, and a stirrer, an amino acid vinyl monomer, and if necessary, other monomers (b) and a solvent are charged, and the temperature is raised to 70 to 80°C while replacing with nitrogen. The concentration of the monomer component is preferably in the range of 20 to 50% by weight, taking into consideration the shortening of the reaction time and the heat generated during polymerization. After replacing with nitrogen, an initiator is added, and the reaction is carried out under reflux conditions. The reaction time is preferably in the range of 5 to 24 hours, taking into consideration the reaction rate (conversion rate) and the reduction of residual monomer components. The reaction rate (conversion rate) is preferably 98% or more. The completion of the reaction and the confirmation of residual monomers can be confirmed by a general analysis method such as gas chromatography. After the reaction is completed, the reaction is cooled to obtain the desired amino acid polymer.

[0053] The polymerization initiator is not particularly limited as long as it has the ability to initiate radical polymerization, and known oil-soluble polymerization initiators and water-soluble polymerization initiators can be used.

[0054] The oil-soluble polymerization initiator is not particularly limited, and examples thereof include organic peroxides such as benzoyl peroxide, tert-butyl peroxybenzoate, tert-butyl hydroperoxide, tert-butyl peroxy (2-ethylhexanoate), tert-butyl peroxy-3,5,5-trimethylhexanoate, and di-tert-butyl peroxide; and azobis compounds such as 2,2'-azobisisobutyronitrile, 2,2'-azobis-2,4-dimethylvaleronitrile, 2,2'-azobis (4-methoxy-2,4-dimethylvaleronitrile), and 1,1'-azobis-cyclohexane-1-carbonitrile. These can be used alone or in combination of two or more. The water-soluble polymerization initiator is not particularly limited, and for example, conventionally known ones such as ammonium persulfate, potassium persulfate, hydrogen peroxide, and 2,2'-azobis(2-methylpropionamidine) dihydrochloride can be suitably used.

[0055] As the solvent used in the polymerization, any solvent can be used as long as it dissolves the amino acid monomer, but considering the removal after polymerization, it is preferable to use water or an alcohol solvent. In addition, if the alcohol solvent used in obtaining the amino acid monomer is directly used in the polymerization step, it can be used as the solvent in the polymerization without being removed from the reaction system.

[0056] <Protein stabilizing or blocking agents> The additive of the present invention is also useful as a protein stabilizer or blocking agent. The uses of the additive as a protein stabilizer and blocking agent are described below. <Protein stabilization method> The protein can be stably stored by allowing the protein stabilizing agent of the present invention to coexist with the protein. The stabilizing agent and the protein can be allowed to coexist by dissolving or dispersing them in a common solvent.

[0057] The solvent in which the stabilizer and the protein coexist is preferably an aqueous solvent. For example, water, phosphate buffered saline, or Tris buffered saline may be used. Water may contain a portion of an organic solvent that is miscible with water, such as methanol, ethanol, propyl alcohol, or tetrahydrofuran.

[0058] The stabilizer of the present invention is preferably present in an amount 100 times, more preferably 10,000 times, the mass of the protein. If the amount of stabilizer added is sufficient, an appropriate stabilizing effect can be exhibited. For the same reason, the content of the stabilizer is preferably 0.01 w / v% or more, more preferably 0.1 w / v% or more, based on the total amount of the solution.

[0059] <Immunoassay method> By using the blocking agent of the present invention, non-specific reactions can be suppressed in immunoassays. In the present invention, blocking refers to preventing non-specific adsorption caused by factors other than the antigen-antibody reaction between the target substance (antigen or antibody) in the specimen and the antigen or antibody against the target substance in immunoassays, and also to preventing the occurrence of carrier aggregation due to the non-specific adsorption. In addition, when the target substance in the specimen is adsorbed to the carrier without the intervention of the antigen or antibody against the target substance, abnormalities in the measured value may occur, and this also includes preventing such abnormalities. Examples of the above immunoassays include diagnosis by latex agglutination, ELISA, chemiluminescence, turbidimetric immunoassay (TIA), radioimmunoassay (RIA), immunochromatography, etc. In the present invention, blocking includes preventing nonspecific adsorption caused by anything other than an antigen-antibody reaction between an antigen contained in the pathological tissue and an antibody against the antigen when the specimen is a pathological tissue. Examples of such immunoassay methods include immunostaining methods.

[0060] The specimen may typically be various biological liquid samples such as serum, plasma, urine, saliva, etc., pulverized specimens of feces or food, pathological tissues, etc. The measurement sample may be a specimen dilution solution prepared by diluting the specimen with a pH buffer solution, protein, amino acid, etc.

[0061] The carrier is not particularly limited as long as it can immobilize an antigen or antibody against the target substance or a target substance (antigen or antibody), and examples of the carrier include ELISA plates, immunochromatography membranes, latex particles, gold colloids, etc. In the case of immunostaining, any substrate capable of immobilizing the pathological tissue as a specimen can be used, and examples of the substrate include petri dishes. The average particle size of the latex particles and gold colloids is preferably 0.01 to 1 μm. Examples of the latex particles include polymer particles derived from monomers such as (meth)acrylamide compounds, (meth)acrylate compounds, unsaturated aldehyde compounds, unsaturated carboxylic acid compounds or unsaturated carboxylic anhydride compounds, unsaturated sulfonic acid compounds, styrene compounds, etc. Among the polymer particles, those which are copolymers of styrene compounds and unsaturated carboxylic acid compounds are preferred.

[0062] The blocking agent is typically used in the form of a solution. The process of treating the carrier containing the antigen or antibody with the blocking agent is not particularly limited, but may be, for example, the following method. First, a carrier is prepared, and the antigen or antibody against the target substance is adsorbed on the carrier, and then the blocking agent is added and brought into contact with the carrier. At this time, the blocking conditions are as follows: The blocking time can be adjusted by holding the blocking solution for a predetermined period of time after it has been added. For example, typical treatment times are 30 minutes to 2 hours when the temperature of the blocking solution added is about 37°C, 1 to 3 hours when it is at room temperature (e.g., about 20°C), and 2 to 12 hours when it is about 4°C. By such a process, a part or the whole of the surface of the carrier containing the antigen or antibody against the target substance can be covered with the blocking agent.

[0063] After the blocking treatment, the target substance (antigen or antibody) is further added to allow the specific antigen-antibody reaction to proceed, after which the label can be measured by a conventional method to obtain the results of the immunoassay.

[0064] In addition, specific blocking methods in immunostaining include, for example, the following method. First, a pathological tissue fixed on the surface of a substrate is prepared, and a blocking agent is added to the tissue and brought into contact with it. In this case, the blocking conditions are similar to those described in the immunoassay method. After blocking, the staining antibody is adsorbed to the antigen in the pathological tissue, and the color intensity and the proportion of stained cells or tissues are evaluated by a conventional method.

[0065] The concentration of the blocking agent solution varies depending on the type of blocking agent, the type of specimen, and the type of carrier, but can generally be 0.01 w / v% to 3 w / v% based on the total amount of the solution. The solvent used can be a water-soluble solvent that is usually used for this purpose, and examples of the solvents used in the binding treatment of physiologically active substances include water, physiological saline, acetate buffer, citrate buffer, phosphate buffer, HEPES buffer, and MES buffer. If the amount of the blocking agent added is sufficient, an appropriate blocking effect can be achieved. The content of the blocking agent is preferably 0.1 w / v% or more based on the total amount of the solution.

[0066] <Kit> The kit for immunoassay of the present invention comprises at least a carrier containing an antigen or antibody against a target substance, which is partially or completely coated with a blocking agent. The kit of the present invention can be used in the immunoassay method of the present invention in the same manner as a kit for use in detecting a target substance in a sample by a conventional immunoassay.

[0067] <Cell culture medium additives> The additive of the present invention is also useful as an additive for a cell culture medium. The use of the additive as an additive for a cell culture medium is described below.

[0068] By culturing cells in a medium containing the cell culture medium additive of the present invention, the functions of the cells can be improved, and in particular, the production of physiologically active substances can be improved.

[0069] <Cell Culture Media> As the cell culture medium to which the cell culture medium additive of the present invention is added, a conventionally known cell culture medium can be used, for example, various commercially available media (αMEM, MEM, DMEM, IMDEM, RPMI1640, DMEM / F12, etc.) and combinations thereof.

[0070] The concentration of the amino acid polymer (A) in the cell culture medium is preferably 0.001 to 1 mass %, more preferably 0.01 to 1 mass %, and even more preferably 0.05 to 1 mass %. It is preferable to add various growth factors (e.g., epidermal growth factor, insulin-like growth factor, nerve growth factor, hepatocyte growth factor, vascular endothelial growth factor, basic fibroblast growth factor, transferrin, steroid hormones, 2-mercaptoethanol, etc.), various animal sera (e.g., fetal bovine serum (FBS) and bovine serum), serum substitutes, etc. to the cell culture medium as necessary.

[0071] <Method of producing physiologically active substances> By culturing cells in the cell culture medium of the present invention, a physiologically active substance can be produced with high efficiency. The method for producing a physiologically active substance according to this embodiment includes culturing cells using a cell culture medium containing the cell culture medium additive containing the amino acid polymer (A) described above.

[0072] The physiologically active substance according to the present embodiment is, for example, an antibody protein (hereinafter referred to as an antibody) or albumin. The antibody produced here is not particularly limited, and is, for example, a mouse monoclonal antibody, a humanized monoclonal antibody, or a human monoclonal antibody. The immunoglobulin class is not particularly limited, and is, for example, IgG (for example, IgG1, IgG2, etc.).

[0073] <Cells cultured in cell culture medium> The cells to be cultured in the cell culture medium are not particularly limited, and may be any cells that can be used to produce a physiologically active substance. In particular, cells capable of producing antibodies include CHO cells, BHK cells, HepG2 cells, rodent myeloma cells (such as mouse myeloma cells, such as SP2 / O cells and NSO cells), hybridomas, and transformed cells obtained by introducing a foreign gene into these cells.

[0074] In the present invention, when culturing, a vessel or device usually used for culturing can be used, such as a multi-well plate, a petri dish, a culture flask, a spinner flask, a jar fermenter, a fermenter, a roller bottle, a hollow fiber, a microcarrier, etc.

[0075] The culture conditions in this embodiment may be the same as those for ordinary animal cell culture conditions, for example, conditions of 5% by volume CO2 atmosphere and a temperature of 37°C.

[0076] To harvest cells from the culture medium, suspension cells can be collected by, for example, directly centrifuging or filtering the culture medium, whereas adherent cells can be collected by, for example, suspending the cells by adding 0.25 w / v% trypsin-0.02 w / v% EDTA solution, and then collecting the cells by centrifugation or filtration.

[0077] When a physiologically active substance, particularly an antibody, is produced by cell culture and accumulates in the culture medium, the supernatant is obtained by filtration or centrifugation and then collected. When the substance accumulates within cells, the cells obtained by filtration or centrifugation are homogenized, sonicated, or treated with chemicals to obtain a supernatant from which the product is extracted.

[0078] The antibody can be separated and purified from the supernatant by an appropriate combination of known methods, such as ammonium sulfate precipitation, dialysis, ultrafiltration, electrophoresis, gel filtration, ion exchange chromatography, reverse phase chromatography, and affinity chromatography.

[0079] <Cell cryoprotectant> The additive of the present invention is also useful as a cell cryoprotectant. Its use as a cell cryoprotectant will be described below.

[0080] <Cell cryopreservation solution> The cell cryopreservation agent of the present invention can be mixed with, for example, a low molecular weight solvent to prepare a cell cryopreservation solution. The cell cryopreservation solution contains an amino acid polymer (A), preferably contains a low molecular weight solvent, and preferably does not contain natural animal-derived components. In addition, the cell cryopreservation solution is believed to be able to improve the survival rate of cells by preventing ice crystal formation by promoting dehydration of cells into the cell membrane during the freezing process. For this reason, the osmotic pressure of the cell preservation solution is set to 500 to 2,500 mOsm / kg. is preferable, more preferably 1,000 to 2,500 mOsm / kg, and even more preferably 1,500 to 2,300 mOsm / kg. The osmotic pressure of the cell cryopreservation solution is determined by the concentration of all substances, including ions, contained in the cell cryopreservation solution. The osmotic pressure of the cell culture medium can be adjusted to 310 to 360 mOsm / kg by the amino acid polymer contained therein, but the osmotic pressure of the cell cryopreservation solution can be appropriately adjusted by later adding low molecular weight compounds or low molecular weight solvents contained in the cell culture medium, such as sugars, amino acids, and vitamins. By using the cell cryopreservation solution of the present invention, cell aggregates such as colonies of ES cells or iPS cells or three-dimensionally cultured (stem) cell spheroids can be frozen and transported more simply and efficiently.

[0081] <Cells to be cryopreserved> The cells used in this specification are not particularly limited as long as they are cells that can be cryopreserved, and may be any of microorganisms, bacteria, animal cells, and plant cells. Animals as used herein include mammals including humans, fish, birds, insects, etc. The "animal cell" in the present invention may be of any type, such as a cell line established as a cultured cell, an unestablished normal cell obtained from a biological tissue, or a transformed cell obtained by a genetic engineering technique. The cell includes any type of cell, such as somatic cells, such as all types of cells in a tissue or organ; stem cells of all types, such as totipotent stem cells, pluripotent stem cells (e.g., iPS cells, ES cells), and progenitor cells; oocytes; sperm; and germ cells. The cells may be in isolated form or in the form of cell-containing body fluids, non-isolated cell aggregates such as cell colonies or 3D cultured (stem) cell spheroids, tissues, or organs.

[0082] The cell cryopreservation solution of the present invention preferably contains 0.1 to 30.0 w / v % of amino acid polymer (A), more preferably 1.0 to 20.0 w / v %. By making the content of the amino acid polymer 1.0 w / v % or more, it is advantageous to exert a sufficient cryoprotective effect by the nonfreezing water. By making the content of the compound 20.0 w / v % or less, the amino acid polymer can be stably dispersed in the cell cryoprotectant.

[0083] <Low molecular weight solvent> The cell cryopreservation solution according to the present invention preferably contains a low molecular weight solvent. Examples of low molecular weight solvents include dimethyl sulfoxide (DMSO), ethylene glycol (EG), propylene glycol (PG), and glycerin. These may be used in combination of two or more. Having a low molecular weight solvent is advantageous in obtaining a sufficient cryoprotective effect. The content of the low molecular weight solvent in the cell cryopreservation solution according to the present invention can be appropriately changed depending on the type of components used, but is preferably an amount such that the final concentration is 5.0 w / v% or less. If it is 5.0 w / v% or less, it is preferable because it has low toxicity to cells. In addition, it is preferable not to include DMSO because it may affect differentiation.

[0084] <Natural animal-derived ingredients> The cell cryopreservation solution of the present invention is preferably free of natural animal-derived components. Examples of natural animal-derived components include albumin, serum, plasma, and basal medium. Examples of serum include adult bovine serum, calf serum, newborn calf serum, and fetal bovine serum. Since the cell cryopreservation solution of the present invention does not contain natural animal-derived components, there is no problem of quality differences between lots of natural animal-derived components, and it is possible to avoid changes in cell properties due to components that are not actually necessary for cell preservation, such as various cytokines, growth factors, and hormones contained in serum, and it is also possible to avoid the effects of components in the basal medium of unknown origin. Therefore, the cell cryopreservation solution of the present invention is extremely useful from the viewpoint of being able to be safely applied to living organisms, particularly in clinical use. Moreover, as will be shown in the examples described below, it is possible to avoid the effects of natural Even though the medium does not contain any natural animal-derived components, cells can be cryopreserved with good viability.

[0085] <Culture medium in cell cryopreservation solution> The cell cryopreservation solution according to the present invention preferably contains a cell culture medium. The type of cell culture medium is not particularly limited, and a person skilled in the art in this technical field can appropriately select a medium capable of culturing the cells, but the cell culture medium components are preferably components of a basal medium for animal tissue culture that does not contain natural animal-derived components. Examples of the medium include αMEM, MEM, DMEM, IMDEM, RPMI1640, DMEM / F12, etc. In addition, the cell cryopreservation solution according to the present invention may contain only medium components other than the low molecular weight solvent and the compound, since the higher the medium content, the lower the cytotoxicity.

[0086] <Other> The cell cryopreservation solution of the present invention may contain components other than the amino acid polymer and the low molecular weight solvent, and other components that can be suitably used are those contained in cell culture media, etc. Examples of such components include sugars, amino acids, vitamins, antioxidants, trace elements, etc. As the sugar, glucose, sucrose, etc. are preferred. Vitamins include B vitamins such as biotin, pantothenic acid, choline, folic acid, myo-inositol, niacin, pyridoxine, riboflavin, thiamine, and cobalamin. Antioxidants include glutathione, ascorbic acid, and the like. Trace elements include Ag+, Al3+, Ba2+, Cd2+, Co2+, Cr3+, Ge+, M These include n2+, Mo6+, Ni2+, Rb+, Se4+, Si4+, Sn2+, V5+, Zr4+, Br-, F-, and I-. The above-mentioned components such as amino acids, vitamins, antioxidants, and trace elements may be used in combination of two or more kinds, and each component may be used in two or more kinds. Furthermore, a pH adjusting agent may be included. Examples of pH adjusting agents include phosphate buffer and carbonate buffer. When a phosphate buffer is not added to Basic Stock Solution (BSS), a solution containing physiological saline may also be used. Among these, it is particularly preferable to use a phosphate buffer. It is preferable to use a pH adjusting agent appropriately to adjust the pH of the cell cryopreservation solution to about 6.5 to 9.0, preferably 7.0 to 8.5. The phosphate buffer in the present invention refers to sodium chloride, monosodium phosphate (anhydrous), monopotassium phosphate (anhydrous), disodium phosphate (anhydrous), trisodium phosphate (anhydrous), potassium chloride, and potassium dihydrogen phosphate (anhydrous), and it is particularly preferable to use sodium chloride, monosodium phosphate (anhydrous), potassium chloride, or potassium dihydrogen phosphate (anhydrous). A combination of potassium dihydrogen phosphate, sodium chloride, potassium chloride, and disodium hydrogen phosphate is also preferable. The pH adjusting agent is preferably contained in the cell preservation solution at 0.01 to 1.0 w / v%, more preferably at 0.05 to 0.5 w / v%.

[0087] <Sterilization> The cell cryopreservation solution according to the present invention is preferably sterilized. This reduces the risk of bacterial infection and allows for safer application to living organisms. Any method of sterilization may be used as long as it does not denature or decompose the components of the cell cryopreservation solution, and filter sterilization is preferred.

[0088] <Cell freezing method> The method for freezing cells using the cell preservation solution of the present invention is not particularly limited, but preferably includes a mixing step of mixing the cell cryopreservation solution with cells, and a freezing step of freezing the mixture of the cell cryopreservation solution and cells. Before the mixing step, the cells may be washed with a washing solution such as PBS (phosphate buffered saline). This can further reduce contamination with components of the culture medium, for example. In the mixing step, the number of cells per 1 mL of the cell cryopreservation solution is not particularly limited, but is preferably 10 3 ~10 9 / mL, more preferably 10 4 ~10 8 It is preferable to prepare the solution so that the concentration becomes 1 / mL. In addition, in the mixing step of cell aggregates (colonies, spheroids), the number of cell aggregates per 1 mL of the cell cryoprotectant is not particularly limited, but is preferably 1 to 10 5 / mL, more preferably 1 to 10 3 It is preferable to prepare the solution so that the concentration becomes 1 / mL. The mixture is transferred to a cold-resistant container such as an ampoule or a cryotube, and thoroughly pipetted on ice. The cold-resistant container is preferably sterilized inside. In the freezing step, the cooling rate is not particularly limited. However, for example, if the cells are cooled rapidly, there will be a difference in the freezing rate of water inside and outside the cells, which may destroy the microstructure of the cells. Therefore, it is preferable to set the cold-resistant container in a temperature-controllable freezer or slow freezing container and cool the cells at a rate of 0.5°C to 3°C per minute. Examples of temperature-controllable freezers or slow freezing containers include CoolCell (registered trademark) from Wakembie Tech Co., Ltd., Mr. Frosty from Nalgene Co., Ltd., and Bycell from Nippon Freezer Co., Ltd. The final freezing temperature is not particularly limited, but is preferably -80°C or lower, more preferably -150°C or lower, and even more preferably -196.5°C or lower. After storage at around -80°C, the cells may be transferred to -180°C to -200°C (for example, in liquid nitrogen) and stored. This allows frozen cells to be obtained. For cell aggregates such as cell colonies and spheroids, a method may be used in which the inside of the cells is dehydrated and replaced, and the temperature is rapidly lowered to liquid nitrogen temperature to vitrify and fix the entire cells. For example, a frozen cell aggregate can be obtained by directly immersing a cold-resistant container in liquid nitrogen. The cell cryopreservation solution of the present invention may be combined with, for example, a cold-resistant container, a temperature-controllable freezer or slow-freezing container, or instructions for use, etc., to prepare a kit. The instructions for use of the kit include, for example, the above-mentioned cryopreservation method, etc.

[0089] <Frozen cells> The frozen cells of the present invention can achieve good survival and proliferation rates, for example, after one week or more of storage (e.g., after 10 days or more, 10 years or more). The survival rate after thawing of the present invention is defined as cell survival rate=number of live cells / (number of live cells+number of dead cells)×100% immediately after thawing. The survival rate after thawing is 50% or more, preferably 60% or more, more preferably 70% or more, even more preferably 80% or more, and particularly preferably 90% or more. Immediately after thawing means within 12 hours after thawing. The proliferation rate after thawing in the present invention is defined as cell proliferation rate = number of cells 3 days after thawing / number of cells seeded at the initial stage of thawing x 100%. The proliferation rate is 105% or more, preferably 150% or more, and more preferably 200% or more.

[0090] <Thawing cells> As described above, cells cryopreserved using the freezing method or preservation method of the present invention can exhibit good survival and proliferation rates after thawing (see also the Examples described below). Thawing is preferably performed quickly, for example, by immersing the cells in a water bath at 37°C ± 1°C. When using the cells after thawing, the cell cryoprotectant may or may not be removed. EXAMPLES

[0091] The present invention will be described in more detail below with reference to examples, but the following examples are not intended to limit the scope of the invention. In the examples and comparative examples, the term "mol" refers to the amount of a substance. The mol% indicates the proportion of the substance in the total monomers.

[0092] [Production Example 1] Amino acid monomer 1 In a four-neck flask, L-glycine (10.0 g, 0.133 mol), sodium hydroxide (10.7 g, 0.266 mol), and 25 mL of water were placed and dissolved. The reaction solution was placed in an ice bath. The mixture was cooled in an ice bath, and acryloyl chloride (13.26 g, 0.147 mol) was added dropwise over 1 hour. After the dropwise addition, the mixture was stirred in an ice bath for 30 minutes, and then stirred at room temperature for an additional 2 hours. The reaction mixture was adjusted to pH 1-2 by adding aqueous hydrochloric acid, and then extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained solid was further washed with diethyl ether, filtered, and dried under reduced pressure for 24 hours to obtain amino acid monomer 1 (12.12 g, 70.5%) having the following structure. Amino acid monomer 1 [ka]

[0093] [Manufacturing Examples 2 to 5] Amino acid monomers 2-5 Amino acid monomers having the following structures were obtained in the same manner as in Production Example 1, except that the materials were changed as shown in Table 1. The amino acids used were in the same molar amount as L-glycine in Production Example 1. Amino acid monomers 2, 3, 5 [ka] Amino acid monomer 4 [ka]

[0094] [Table 1]

[0095] [Production Example 6] Amino acid monomer 6 In a reaction vessel equipped with a stirrer, a thermometer, a reflux condenser, and a dropping funnel, glycine tert-butyl hydrochloride (54.9 g, 0.327 mol), sodium hydroxide (19.6 g, 0.491 mol), and 100 mL of ethanol were placed. The mixture was heated to 70°C while stirring to dissolve, and then cooled to 40°C. 4-Chloromethylstyrene (52.8 g, 0.344 mol) was added dropwise from the dropping funnel over 1 hour. The reaction temperature was maintained at 40°C and the reaction was allowed to proceed for 6 hours. After the reaction, the solution was filtered and the filtrate was separated. Ethyl acetate was added to the filtrate little by little, and the mixture was cooled to cause recrystallization. The obtained crystals were dissolved in ethanol again, recrystallized with ethyl acetate, and then dried under reduced pressure at room temperature for 24 hours to obtain the amino acid monomer precursor 1 (84.21 g, 80.3%) of the following structure. Amino acid monomer precursor 1 [ka]

[0096] In a reaction vessel equipped with a stirrer, a thermometer, a reflux condenser, and a dropping funnel, amino acid monomer precursor 1 (89.7 g, 0.280 mol) and 100 mL of dichloromethane were placed and dissolved. The reaction solution was cooled in an ice bath, and trifluoroacetic acid (63.9 g, 0.560 mol) was added dropwise over 30 minutes. After the addition, the mixture was stirred at room temperature for another 2 hours. After the reaction, dichloromethane was removed by vacuum concentration, and the mixture was recrystallized with acetone. The mixture was then dried under reduced pressure at room temperature for 24 hours to obtain amino acid monomer 6 (45.72 g, 85.4%) of the following structure. Amino acid monomer 6 [ka]

[0097] [Production Example 7] Amino acid monomer 7 An amino acid monomer precursor 2 having the following structure was obtained in the same manner as in Production Example 6, except that the materials were changed to those shown in Table 2. The amino acid was used in the same molar amount as that of glycine tert-butyl hydrochloride in Production Example 6. Amino acid monomer precursor 2 [ka]

[0098] Next, amino acid monomer 7 having the following structure was obtained in the same manner as in Production Example 6, except that the materials were changed to those shown in Table 2. The amino acid precursor was used in the same molar amount as amino acid monomer precursor 1 in Production Example 6. Amino acid monomer 7 [ka]

[0099] [Production Example 8] Amino acid monomer 8 Amino acid monomer 8 having the following structure was obtained in the same manner as amino acid monomer precursor 1 in Production Example 6, except that glycine tert-butyl hydrochloride was changed to L-proline. In addition, L-proline was used in the same molar amount as glycine tert-butyl hydrochloride in Production Example 6. Amino acid monomer 8 [ka]

[0100] [Table 2]

[0101] [Production Example 9] · Difunctional monomer 1 A reaction vessel equipped with a reflux condenser and a stirrer was charged with 4-hydroxybutyl acrylate (138.0 g, 0.957 mol) and 80 mL of pyridine. While cooling with ice, methacrylic acid chloride (110.1 g, 1.05 mol) was added dropwise over 1 hour. After reacting for 4 hours, the solution was filtered and the filtrate was distilled under reduced pressure to obtain a bifunctional monomer 1 (130.0 g, 64.0%) having the following structure. Difunctional monomer 1 [ka]

[0102] [Examples 10-12] Bifunctional monomers 2-4 Except for changing the materials shown in Table 3, the same method as in Production Example 9 was used to obtain bifunctional monomers having the following structures. Bifunctional monomer 2 [ka] Difunctional monomer 3 [ka] Difunctional monomer 4 [ka]

[0103] [Table 3]

[0104] The hydroxyl-containing acrylates listed in Table 3 are shown below. Polyethylene glycol monoacrylate: NOF Corp., Blenmar AE-90U Polypropylene glycol monoacrylate: NOF Corp., Blenmar AP-200

[0105] [Production Example 13] Amino acid monomer 9 In a reaction vessel equipped with a reflux condenser and a stirrer, bifunctional monomer 1 (89.06 g, 0.420 mol), glycine tert-butyl hydrochloride (72.1 g, 0.225 mol), and 120 mL of ethanol were charged. After heating with stirring, the mixture was reacted at 70°C for 5 hours. After the reaction was completed, the ethanol was removed by drying under reduced pressure, and the mixture was recrystallized with acetone to obtain amino acid monomer precursor 3 (96.11 g, 88.0%) having the following structure. Amino acid monomer precursor 3 [ka]

[0106] Amino acid monomer 9 having the following structure was obtained in the same manner as in Production Example 6, except that amino acid monomer precursor 1 in Production Example 6 was changed to amino acid monomer precursor 3. Amino acid monomer 9 [ka]

[0107] [Examples 14 and 15] Amino acid monomers 10, 11 Amino acid monomers 10 and 11 were obtained in the same manner as in Production Example 12, except that the materials were changed as shown in Table 4.

[0108] [Table 4] Amino acid monomer 10 [ka] Amino acid monomer 11 [ka]

[0109] [Production Example 16] Amino acid monomer 12 Amino acid monomer 12 having the following structure was obtained in the same manner as amino acid monomer precursor 9 in Production Example 13, except that glycine tert-butyl hydrochloride was changed to L-proline and bifunctional monomer 1 was changed to bifunctional monomer 4. In addition, L-proline was used in the same molar amount as glycine tert-butyl hydrochloride in Production Example 13. Amino acid monomer 12 [ka]

[0110] [Polymer Production Example 1] Amino acid polymer 1 A reaction vessel equipped with a stirrer, a thermometer, a dropping funnel, and a reflux condenser was charged with 150 parts of ethanol, and the internal temperature was raised to 75°C and thoroughly replaced with nitrogen. 0.4 parts of azobisisobutylnitrile and 100 parts of (amino acid monomer 1), which had been prepared separately, were added dropwise for 3 hours while maintaining the temperature at 75°C, and stirring was continued for another 8 hours. After the reaction was completed, the mixture was cooled and taken out. Then, the ethanol was completely evaporated by drying under reduced pressure, and amino acid polymer 1 was obtained.

[0111] [Polymer Production Examples 2-16] Amino acid polymers 2 to 16 were obtained using the blending compositions shown in Table 5 in the same manner as in Polymer Production Example 1. In the table, the figures other than the mass average molecular weight and the amount of unfreezed water indicate the number of parts.

[0112] 1 g of the obtained amino acid polymers 1 to 16 was placed in 100 mL of ion-exchanged water at 25°C. After dissolving the resins by stirring, the resins were left to stand for 24 hours at 25° C. As a result, no separation or precipitation was observed, indicating that the resins were completely soluble and water-soluble.

[0113] <Measurement of mass average molecular weight (Mw)> The weight average molecular weight is shown in Table 5 as a value calculated as polyethylene glycol by GPC (gel permeation chromatography). Apparatus: GPCSYSTEM24H (Showa Denko Co., Ltd.) Column: SB-803HQ + SB-804HQ (Showa Denko) Dissolution medium: 20 mM phosphate buffer Standard material: Polyethylene glycol (Agilent Technologies) Flow rate: 0.5 mL / min, sample solution volume: 10 μL, column temperature: 40°C

[0114] <Measurement of nonfreezing water> -Measurement of non-freezing water in amino acid polymers For the amino acid polymers 1 to 16, an aqueous solution was prepared in which the concentration of the amino acid polymer was 20.0 w / v%. This aqueous solution was used as a sample for measuring the amount of nonfreezing water. The amount of nonfreezing water contained in the amino acid polymer was measured using a method described in detail in JP 2016-063801 A. In the invention described in this specification, a differential scanning calorimeter (DSC device; Hitachi High-Tech Science DSC6200) was used to measure the transfer of latent heat in polymers containing water at various ratios under conditions of a nitrogen flow rate of 50 mL / min and 5° C. / min. The temperature program consisted of (i) cooling from room temperature to -100°C, (ii) holding at -100°C for 5 minutes, and (iii) heating from -100°C to 30°C. In the above (iii), the presence or absence of free water and intermediate water was confirmed by the presence or absence of an exothermic peak due to low-temperature crystallization of water and an endothermic peak due to low-temperature melting of water. In other words, in the DSC chart, the release of latent heat near -40°C and the absorption of latent heat below the freezing point of -20°C or lower are believed to be due to the ordering and re-disordering of the intermediate water contained in the amino acid polymer. Using a DSC device, the aluminum oxide pan was cooled from room temperature to -100°C, held there for 5 minutes, and then heated from -100°C to 30°C at a temperature increase rate of 5°C / min. The amount of heat absorbed and released during this process was measured. After the DSC measurement, each sample was vacuum-dried in an aluminum pan with a pinhole, and then weighed. The weight loss was recorded as the water content. The moisture content (WC) is calculated using the following formula (I), excluding the mass of the aluminum oxide pan. Moisture content (WC)=(W1-W0) / W0(I) (W0: dry weight of sample (g), W1: wet weight of sample (g)) For each sample, the amount of free water was calculated from the endothermic heat near 0°C, and the amount of intermediate water was calculated from the amount of heat generated near -40°C and the endothermic heat at freezing points of -20°C or higher. The amount of unfreezable water was calculated by subtracting the amount of free water and intermediate water from the water content (W1-W0) of each sample calculated above. The amount of unfreezable water per gram of amino acid polymer was calculated by dividing the amount of unfreezable water calculated by the dry weight (W0) of the sample. The results of the experiment are shown in Table 5.

[0115] [Table 5]

[0116] The monomers (b) listed in Table 5 are shown below. BMA: n-Butyl methacrylate HEA: Hydroxyethyl acrylate AA: Acrylic acid

[0117] The evaluation of the compound as a protein stabilizer and a blocking agent is shown below.

[0118] <Preparation of protein stabilizer aqueous solution>

[0119] [Examples 1-1 to 1-18, Comparative Examples 1-1 to 1-2] (Protein stabilizer aqueous solution 1-20) The amino acid polymers 1 to 16 obtained in Polymer Production Examples 1 to 16, polyvinylpyrrolidone (hereinafter PVP), and proline were adjusted with phosphate buffered saline (hereinafter PBS solution) to the concentrations shown in Table 6 to obtain protein stabilizer aqueous solutions 1 to 18. PVP: Polyvinylpyrrolidone, weight average molecular weight 10,000

[0120] <Evaluation of protein stabilizers> The obtained protein stabilizer was evaluated as follows, and the results are shown in Table 6.

[0121] [Preparation of enzyme aqueous solution for evaluation] The HRP-labeled anti-CRP antibody ab24462 (Abcam) was diluted and mixed with 1 mL of the protein stabilizer solution to a concentration of 8.0 ng / mL to prepare an enzyme aqueous solution for evaluation. The enzyme aqueous solution for evaluation was tightly sealed and stored in a dark place at 25°C to prevent any change in concentration.

[0122] [Enzyme activity evaluation] A peroxidase color development kit (Sumitomo Bakelite Co., Ltd.) was used to develop the color development agent (3,3',5 A color-developing solution was obtained by mixing 10 mL of a 5'-tetramethylbenzidine (TMBZ) solution and 100 μL of a substrate solution (hydrogen peroxide solution). 100 μL of this coloring solution and 100 μL of the enzyme aqueous solution for evaluation were added to a 96-well plate and left to stand in the dark at 30°C for 20 minutes. 100 μL of a stop solution (sulfuric acid aqueous solution) was added to this to stop the reaction. Then, the absorbance at 450 nm was measured using a plate reader Multimode Reader Mithras 2LB943 (manufactured by BERTHOLD TECHNOLOGIES) to quantify the amount of TMBZ oxide produced by the reaction. Since the oxidation reaction of TMBZ correlates with the activity of the HRP-labeled CRP antibody, the obtained absorbance can be used as an index of enzyme activity.

[0123] [Evaluation of protein stabilization effect] The enzyme activity evaluation was carried out twice, once before storage of the enzyme aqueous solution for evaluation and once after storage at 25°C for 30 days, and the absorbance was measured. The absorbance before storage was taken as 100%, and the ratio of the absorbance after storage was calculated as the relative absorbance, and the denaturation of the protein was evaluated according to the following criteria. The results are shown in Table 6.

[0124] Relative absorbance after 30 days of storage ◎: 95% or more (very good) ○: 90% or more, less than 95% (good) △: 80% or more, less than 90% (usable) ×: Less than 80% (unusable)

[0125] [Table 6]

[0126] As shown in Table 6, a high protein stabilization effect was obtained by using the protein stabilizer of the present invention. Specifically, the protein stabilizers using the amino acid polymers 1 to 16 In Examples 1-1 to 1-18, the change in absorbance after 30 days of storage at 25°C was small compared to the absorbance before storage, and the protein structure stabilization effect was confirmed. On the other hand, it was found that in Comparative Examples 1-1 to 1-2, which used PVP or proline, sufficient stabilization effect was not obtained even when stored in the presence of protein. This is thought to be because the external environment of the protein could not be appropriately controlled because they did not have amino acid residues or were simple amino acids.

[0127] <Preparation of blocking agent aqueous solution>

[0128] [Examples 2-1 to 2-18, Comparative Examples 2-1 to 2-2] (Blocking agent aqueous solution 1-20) The amino acid polymers 1 to 16 produced in Polymer Production Examples 1 to 16, PVP, and proline were adjusted with a PBS solution to have concentrations as shown in Table 7, to obtain blocking agent aqueous solutions 1 to 20.

[0129] <Evaluation of blocking agents> The obtained blocking agent solution was subjected to the antigen-antibody reaction test and the non-specific adsorption test as described below, and was evaluated based on the difference in absorbance. The results are shown in Table 7.

[0130] [Antigen-antibody reaction test] (Solid-phase antibody treatment of well plates) The solid-phase anti-CRP antibody ab8279 (Abcam) was adjusted to a concentration of 25 μg / mL with PBS solution. 50 μL of this solid-phase anti-CRP antibody solution was added to a PSt 96-well plate and left at room temperature for 2 hours, after which the solution was aspirated and removed.

[0131] (Blocking process) The obtained blocking agent solution was added to the 96-well plate treated with the solid-phase antibody in an amount of 200 μL each, and then aspirated and removed, and this process was repeated three times. Finally, 50 μL of the blocking agent solution was added to each well, and the plate was left to stand at room temperature for 2 hours, after which the solution was aspirated and removed.

[0132] (Antigen adsorption treatment) CRP antigen 8C72 (Hytest) was adjusted to 2 μg / mL with PBS solution. 50 μL of this CRP antigen solution was added to the 96-well plate that had been blocked as described above, and after standing at 30° C. for 2 hours, the solution was aspirated and removed. Then, in order to remove excess antigen, the obtained aqueous blocking agent solution was added in 200 μL portions and aspirated and removed three times.

[0133] (Labeled antibody adsorption treatment) The HRP-labeled anti-CRP antibody ab24462 (Abcam) was adjusted to 0.08 μg / mL with PBS solution. 50 μL of this HRP-labeled anti-CRP antibody solution was added to the antigen-treated 96-well plate described above, left to stand at room temperature for 2 hours, and then the solution was aspirated and removed. Then, in order to remove excess labeled antibody, the obtained blocking agent solution was added in 200 μL portions and aspirated and removed three times.

[0134] (Color reaction) A color development solution was prepared using 10 mL of coloring agent and 0.1 mL of substrate solution from a peroxidase color development kit (manufactured by Sumitomo Bakelite Co., Ltd.). 100 μL of this color development solution was added to the 96-well plate that had been treated with the labeled antibody adsorption treatment described above, and left to stand for 20 minutes in a dark place at 30°C. Next, 100 μL of the stop solution (sulfuric acid aqueous solution) from the peroxidase color development kit (manufactured by Sumitomo Bakelite Co., Ltd.) was added to each well.

[0135] (Absorbance A measurement) The absorbance at 450 nm of each well (absorbance A) was measured. This absorbance represents the amount of antibody adsorbed to the well by the antigen-antibody reaction (specific adsorption).

[0136] [Non-specific adsorption test] (Solid-phase antibody treatment of well plates) The solid-phase anti-CRP antibody ab8279 (Abcam) was adjusted to a concentration of 25 μg / mL with PBS solution. 50 μL of this solid-phase anti-CRP antibody solution was added to a PSt 96-well ELISA plate, left at room temperature for 2 hours, and then the solution was removed by aspirating.

[0137] (Blocking process) The obtained blocking agent solution was added to the 96-well plate treated with the solid-phase antibody in an amount of 200 μL each, and then aspirated and removed, and this process was repeated three times. Finally, 50 μL of the blocking agent solution was added to each well, and the plate was left to stand at room temperature for 2 hours, after which the solution was aspirated and removed.

[0138] (Labeled antibody adsorption treatment) The HRP-labeled anti-CRP antibody ab24462 (Abcam) was adjusted to 0.08 μg / mL with PBS solution. 50 μL of this HRP-labeled CRP antibody solution was added to the 96-well plate that had been blocked as described above, and after leaving it at room temperature for 2 hours, the solution was aspirated and removed. Then, in order to remove excess labeled antibody, the obtained blocking agent solution was added in 200 μL portions and aspirated and removed three times.

[0139] (Color reaction) A color development solution was prepared using 10 mL of coloring agent and 0.1 mL of substrate solution from a peroxidase color development kit (manufactured by Sumitomo Bakelite Co., Ltd.). 100 μL of this color development solution was added to the 96-well plate that had been treated with the labeled antibody adsorption treatment described above, and left to stand for 20 minutes in a dark place at 30°C. Next, 100 μL of the stop solution (sulfuric acid aqueous solution) from the peroxidase color development kit (manufactured by Sumitomo Bakelite Co., Ltd.) was added to each well.

[0140] (Absorbance B measurement) The absorbance at 450 nm of each well (absorbance B) was measured. This absorbance represents the amount of antibody adsorbed to the well due to non-specific adsorption of the labeled antibody in the absence of antigen.

[0141] [Evaluation Criteria] ◎:1.0≦(Absorbance A-Absorbance B): Good 〇:0.8≦(Absorbance A-Absorbance B)<1.0: Usable △:0.5≦(Absorbance A-Absorbance B)<0.8: Unusable ×: (Absorbance A - Absorbance B) <0.5: Poor

[0142] [Table 7]

[0143] As shown in Table 7, by using the blocking agent of the present invention, non-specific reactions were prevented, and immunoassays with high detection sensitivity were able to be performed. Specifically, the blocking agents using amino acid polymers 1 to 16 (Examples 2-1 to 2-18) showed a large difference in absorbance between the CRP antigen-antibody reaction and the non-specific adsorption reaction, and the CRP antigen-antibody reaction was able to be detected with high sensitivity. That is, this is believed to be because the amino acid polymers contained in the blocking agent of the present invention have amino acid residues, and therefore the interaction with the antibody is appropriately controlled, so that the antigen-antibody reaction of CRP is not inhibited, and non-specific adsorption reactions other than the CRP antigen-antibody reaction can be suppressed.

[0144] Next, an evaluation of cell culture medium additives is shown below.

[0145] <Preparation of cell culture medium> [Examples 3-1 to 3-18, Comparative Examples 3-1 to 3-2] (Cell Culture Media 1-20) Amino acid polymers 1 to 16 (polymer production examples 1 to 16), PVP, and methionine were added to the respective basal media described below to the concentrations shown in Table 8, and cell culture media 1 to 20 were obtained by pipetting.

[0146] <Evaluation of cell culture medium additives> The cell culture medium additives were evaluated as follows, and the results are shown in Table 8.

[0147] <Inhibition of the formation of antibody-producing cell aggregates> The medium used was DynamisMedium (Gibco), containing L-Glutamin. The cell suspension was added to a concentration of 1,000,000 cells / mL. This will be referred to as the basal medium hereafter. Two sets of this were prepared, and cell culture medium additives containing amino acid polymers were added to each set to the concentrations shown in Table 8. An IgG gene was introduced into each basal medium, and a CHO cell line secreting and producing IgG antibodies was added to prepare a cell suspension with a CHO cell line concentration of 1,000,000 cells / mL. 20 mL of the resulting cell suspension was seeded in a 125 mL Erlenmeyer flask and cultured at 37°C. During the culture, 15 mL of the supernatant was collected once every 3 to 4 days before the nutrient source was depleted, and replaced with 15 mL of new basal medium. This was repeated five times. The suppression of the formation of antibody-producing cell aggregates was measured by measuring the amount of the medium in the Erlenmeyer flask after five repeated medium changes. The evaluation was performed by visually observing the area near the surface. ◎: No agglomerates are formed near the liquid surface of the Erlenmeyer flask: Good ○: A small amount of aggregates are formed near the liquid surface of the Erlenmeyer flask: Usable ×: Coagulation occurs uniformly near the liquid surface of the Erlenmeyer flask: Unusable

[0148] <Antibody productivity> CHO cells were cultured in the same manner as in the evaluation of the inhibition of the formation of antibody-producing cell aggregates, and the cell culture solution after five repeated medium changes was centrifuged to collect the medium supernatant. The amount of antibody in the medium was measured using a Human IgG ELISA Quantitation Set manufactured by Bethyl Laboratories, Inc. The amount of DNA in the precipitated cell group was also quantified and calculated as the amount of antibody produced per unit amount of DNA. The results were evaluated as a relative value, with the results when cultured without the addition of cell medium additives containing amino acid polymers being taken as 1. ◎: 1.5 or more (very good) ○: 1.2 or more and less than 1.5 (good) △: 1 or more but less than 1.2 (slightly poor) ×: Less than 1 (bad)

[0149] <Albumin production evaluation> A cell culture medium was prepared by adding a cell culture medium additive containing an amino acid polymer to a 10% FBS-DMEM medium (hereinafter referred to as DMEM medium) to the concentration shown in Table 8 and stirring. Human liver cancer cell line HepG2 cells were seeded in a cell culture medium to which the cell culture medium additive containing the amino acid polymer was added to give a concentration of 250,000 cells / mL, and then dispensed into wells of a 96-well U-bottom microplate so that 200 μL per well was dispensed. The plate was then cultured for 3 days in a stationary state in a CO2 incubator (37°C, 5% CO2). The culture solution containing HepG2 cells after 3 days of culture was collected and centrifuged to collect the medium supernatant. The amount of albumin in the medium was measured using an Albumin ELISA Quantitation Set manufactured by Bethyl Laboratories, Inc. The amount of DNA in the precipitated cell group was also quantified and calculated as the amount of albumin produced per unit amount of DNA. The results were evaluated as a relative value assuming that the results obtained when the cell culture medium additive containing the amino acid polymer (A) was not added were 1. ◎: 1.5 or more (very good) ○: 1.2 or more and less than 1.5 (good) △: 1 or more but less than 1.2 (slightly poor) ×: Less than 1 (bad)

[0150] <Evaluation of drug metabolizing enzyme activity> As in the case of the albumin production evaluation, HepG2 cells were cultured for 3 days. After that, HepG2 cells were washed with PBS solution, and the DMEM medium was replaced. CYP3A4 activity was measured using P450-GloTM CYP3A4 Assay Kits (Promega). Luciferin-IPA was used as the substrate for 4. CYP3A4 activity was measured using a plate reader (Berthold). The amount of DNA in the cells was also quantified, and the CYP3A4 activity per unit amount of DNA was calculated. The results were evaluated as a relative value, with the results when cultured without adding any cell culture medium additives taken as 1. ◎: 1.5 or more (very good) ○: 1.2 or more and less than 1.5 (good) △: 1 or more and less than 1.2 (slightly poor) ×: less than 1 (poor)

[0151] <Gene expression analysis by qRT-PCR method> Similar to the albumin productivity evaluation, HepG2 cells were cultured for 3 days. Then, the HepG2 cells were collected, and total RNA was extracted using the RNeasy Micro Kit (manufactured by QIAGEN). cDNA was synthesized from each extracted total RNA by reverse transcription reaction using ReverTra Ace qPCR RT Master Mix (manufactured by TOYOBO). qRT-PCR was performed using TaqMan probes (manufactured by Life Technologies, CYP3A4: Hs00604506_m1, albumin: Hs00609411_m1) for cDNA and the target genes (CYP3A4 and albumin). GAPDH (manufactured by Life Technologies, Hs02786624_g1) was used as the reference gene. The relative expression level of each gene was calculated using the comparative Ct method based on GAPDH. The results were judged as relative values when the performance when cultured without adding the cell culture medium additive containing the amino acid polymer (A) was set as 1. ◎: 2 or more (very good) ○: 1.2 or more and less than 2 (good) △: 1 or more and less than 1.2 (slightly poor) ×: less than 1 (poor)

[0152] <Sphroid formation evaluation> ​An additive for cell culture containing an amino acid-based polymer (A) was added to DMEM medium at the concentrations described in Table 8, and the cell culture medium was prepared by stirring. Human hepatocellular carcinoma cell line HepG cells were adjusted to 100,000 cells / mL in the cell medium containing the above amino acid-based polymer and seeded into wells of a microplate (PrimeSurface MS-9096U manufactured by Sumitomo Bellerite Co., Ltd.) at 100 μL per well. Thereafter, the plate was cultured in a CO2 incubator (37 °C, 5% CO2) in a static state for 3 days. The spheroid formation ability was determined according to the following criteria by photographing the cell culture state at 40 times magnification with a transmission optical microscope 3 days later and observing the cell morphology. The evaluation results are shown in Table 8. 〇: One spheroid was formed (good) △: Multiple spheroids were formed (slightly poor) ×: No spheroid was formed (poor)

[0153] <ATP activity> An additive for cell culture containing an amino acid-based polymer was added to DMEM medium at the concentrations described in Table 8, and the cell culture medium was prepared by stirring. Human hepatocellular carcinoma cell line HepG2 cells were adjusted to 100,000 cells / mL in the cell culture medium supplemented with the above additive containing an amino acid-based polymer, and dispensed into wells of a 96-well U-bottom microplate at 100 μL per well. Thereafter, the plate was cultured in a CO2 incubator (37 °C, 5% CO2) in a static state for 5 days. The ATP activity was evaluated by performing an ATP assay on days 1 and 5. Specifically, 100 μL of an ATP reagent (ATP measurement reagent for 'clumps': manufactured by Toyo B-net Co., Ltd.) was added to the wells after culture, pipetted 5 times, allowed to stand at room temperature for 5 minutes, and then 100 μL of the reagent·cell lysate was aliquoted into another plate and stirred for 1 minute. The luminescence amount was measured using Mithras LB940 (manufactured by Berthold). The evaluation results are shown in Table 8. ATP activity = (luminescence amount after 5 days of culture) / (luminescence amount after 1 day of culture) × 100 ◎: ATP activity 120% or more ATP activity is quite high (very good) 〇: 50%≦ATP activity<120% ATP activity is high (good) △: 20%≦ATP activity<50% ATP activity is slightly high. (Acceptable) ×: ATP activity < 20%. ATP activity is low (bad).

[0154] [Table 8]

[0155] It was found that Examples 3-1 to 3-18, which used the amino acid polymers 1 to 16 of the present invention, exhibited excellent cell aggregate formation inhibition properties, antibody productivity, albumin productivity, drug metabolizing enzyme activity, gene expression level, spheroid formation properties, and ATP activity of the spheroids. The amino acid polymers having an acid residue appropriately controlled the metabolic activity of cells and the extracellular environment, and are therefore considered to be useful for enhancing the production of physiologically active substances during cell culture. On the other hand, the cell culture additives of Comparative Examples 3-1 and 3-2 were inferior to the cell culture medium additives of Examples 3-1 to 3-18 in all evaluations.

[0156] Next, an evaluation of cell cryoprotectants and cell cryopreservation solutions will be presented below.

[0157] <Preparation of cell cryopreservation solution>

[0158] [Example 4-1] ·Cell cryopreservation solution 1 Amino acid polymer 1 (polymer production example 1) was mixed at 30 w / v%, DMSO at 5 w / v%, and DMEM (product code: 042-32255) manufactured by Fujifilm Wako Pure Chemical Industries, Ltd. at 70 v / v%, and the mixture was pipetted until sufficiently homogenous and dissolved. The mixture was then filtered through a filter to obtain a sterile cell cryopreservation solution 1. [Examples 4-2 to 4-18, Comparative Examples 4-1 to 4-6] Using the compositions shown in Table 9, cell cryopreservation solutions 2 to 24 were obtained in the same manner as in Example 4-1.

[0159] <Osmotic pressure measurement> The osmotic pressure of the cell cryoprotectant solution was measured by the "freezing point depression method" according to the Pharmacopoeia using an osmotic pressure measuring device (osmometer) manufactured by GONOTEC Co., Ltd. The results are shown in Table 9.

[0160] <Cell (single cell) cryopreservation> 9 mL of MEMα medium was dispensed into a 15 mL centrifuge tube to prepare a washing medium. Human adipose tissue-derived mesenchymal stem cells (Takara Bio, C-12977) (passage number: 2) were frozen and stored, and the cryotube containing them was shaken in a 37°C warm water bath to thaw the cells. The thawed cells were added to a 15 mL centrifuge tube containing MEMα medium for washing, and centrifuged (500×g for 3 minutes at room temperature). The supernatant was aspirated, the pellet was tapped, 2 mL of MEMα medium was added, and the cells were seeded on a φ100 mm cell culture dish (AGC Technoglass, 3020-100). The cells were cultured for 3 days at 37°C in a 5% CO2 incubator. After 3 days of culture, 1 mL of trypsin-EDTA solution was added, and the cells were left to stand for 3 minutes at 37°C in a 5% CO2 incubator to detach the cells from the cell culture dish and collect the cells. The second passage cells (passage number: 4) were used as human adipose tissue-derived mesenchymal stem cells (hereinafter also referred to as P-hATMSC cells) in the following experiments. 1 mL of cell cryopreservation solution 1-22 was added to the cryopreservation solution 1-22. The mixture was added to ×106 cells, pipetted several times, and then transferred to a cryotube. The cryotube was then placed in a Mr. Frosty containing an appropriate amount of 2-propanol, the lid was closed, and the tube was stored horizontally in a freezer set at -80°C for 12 hours, and then stored horizontally in a refrigerator set at -152°C for 3 days.

[0161] <Freezing and preserving spheroids (cell aggregates)> The P-hATMSC cells obtained above were cultured on a culture dish, and then detached and collected by trypsin treatment. Then, the cells were seeded at 1000 cells / well on a 96-well U-bottom plate (Sumitomo Bakelite Co., Ltd., PrimeSurface (registered trademark), MS-9096U) and cultured in suspension to induce spheroid formation. After 3 days of culture, spheroids with a diameter of approximately 200 μm were obtained. Fifty spheroids prepared as described above were collected from the culture medium using a micropipette and centrifuged (500 × g, 3 minutes, room temperature), after which the supernatant was aspirated and the pellet was tapped. Cell freezing storage medium (S-1-17) was added to the pellet, and the spheroids were After pipetting several times in the cell freezing medium, the cells were transferred to cryotubes, capped, and stored horizontally in a freezer set at -80°C for 12 hours. After 12 hours, the cells were stored horizontally in a refrigerator set at -152°C for 3 days.

[0162] <Thawing cells> The cryotube was shaken in a 37°C warm water bath to thaw the cells.

[0163] <Evaluation of cell viability> 100 μL of the thawed cell suspension was dispensed and 100 μL of 0.5% trypan blue staining solution was pipetted in. After mixing by pipetting several times, the trypan blue stained cell suspension was placed on a hemocytometer and the number of blue stained dead cells and unstained live cells were counted in four large squares of 1 mm × 1 mm each containing 16 small squares.

[0164] <Evaluation criteria> The percent cell viability was calculated using the following formula: (% Viability) = (number of unstained cells) / (total number of unstained and blue stained cells) ◎: Survival rate % ≥ 90% (particularly good) 〇:90%>Survival rate%≧75% (good) △:75%>Survival rate%≧60% (acceptable) ×:60%>Survival rate% (defective) The evaluation results are shown in Table 9.

[0165] <Single cell proliferation evaluation> DMEM supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin-amphotericin B (both manufactured by Biological Industries) (hereinafter referred to as (DMEM + 10% FBS + 1% PS) medium) was dispensed in 9 mL into a 15 mL centrifuge tube to serve as a washing medium. The thawed cells were added to the washing medium and centrifuged (500 × g for 3 minutes at room temperature). The supernatant was aspirated, the pellet was tapped, 2 mL of (DMEM + 10% FBS + 1% PS) medium was added, and the cells were seeded on a φ35 mm IWAKI adhesive-treated dish manufactured by AGC Technoglass. 100 μL was dispensed before seeding, and the cell number was counted using a hemocytometer. The cells were cultured for 3 days in an incubator at 37 °C and 5% CO2. After 3 days of culture, 0.5 mL of trypsin-EDTA solution was added and the mixture was left to stand for 3 minutes in a 37°C, 5% CO2 incubator to detach the remaining cells from the adhesion treatment. The number of detached cells was counted using a hemocytometer. The cell proliferation rate was calculated by (number of cells after 3 days of culture) / (number of cells seeded)×100%. The evaluation results are shown in Table 9. <Evaluation criteria> ◎: Growth rate % ≥ 200% (particularly good) ○: 200%>Growth rate%≧150% (good) △: 150%>Growth rate%≧105% (Acceptable) ×: 105%>Growth rate% (bad)

[0166] <Assessment of undifferentiation of single cells - quantitative real-time PCR (qRT-PCR)> For the cells used in the proliferation evaluation, total RNA was extracted from the cultures after 3 days of culture with TRIzol reagent (Invitrogen Corporation, Carlsbad, CA. USA), and cDNA was synthesized with PrimeScriptTMRT MasterMix (PerfectRealTime) (Takara, Cat#RR036A) according to the manufacturer's protocol. qRT-PCR was performed in triplicate using TBGreen PremixExTaqII (Takara, RR820A) with a Thermal Cycler Dice RealTime System (Takara TP900). The volume of qRT-PCR was 25 μL, with 1 μL (μg) cDNA and 12.5 μL TB. Contains Green Premix ExTaqII (Takara, RR820A), 1 μL each of specific forward and reverse primers, and 9.5 μL sterile water.

[0167] qRT-PCR was performed at 95°C for 30 s, followed by 40 cycles of 95°C for 5 s and 60°C for 30 s, followed by 95°C for 15 s, 60°C for 30 s, and 95°C for 15 s. Data were analyzed by ΔΔCt ratio quantification. Data were normalized to GAPDH levels and compared to control values.

[0168] The sequences of the primers used are as follows: SSEA1 (also known as Fut4) Forward primer: GCAGGGCCCAAGATTAACTGAC (SEQ ID NO: 1) Reverse primer: AAGCGCCTGGGCCTAAGAA (SEQ ID NO: 2) Sox2 Forward primer: GTTCTAGTGGTACGTTAGGCGCTTC (SEQ ID NO: 3) Reverse primer: TCGCCGGAGTCTAGGCTAAATA (SEQ ID NO: 4) Nanog Forward primer: TGCCTCACACGGAGACTGTC (SEQ ID NO: 5) Reverse primer: AGTGGGTTGTTTGCCTTTGG (SEQ ID NO: 6) Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) (as an internal positive control)

[0169] [Statistical analysis] Data were analyzed by one-way analysis of variance (ANOVA). In case of significant F ratios, Tukey's post hoc test was performed. The significance level was set at P<0.05, and the results are presented as mean±SD unless otherwise indicated. All data are from at least three independent experiments unless otherwise indicated.

[0170] Evaluation criteria for gene expression [SSEA1, Sox2, Nanog] ◎: gene expression level ≦2; gene expression level is quite high. ○: 1.5≦gene expression level<2; gene expression level is high. △: 1≦gene expression level<1.5; gene expression level is slightly high. ×: gene expression level < 1; gene expression level is low.

[0171] <Evaluation of viability of spheroids (cell aggregates)> The thawed spheroids were added to the washing medium and centrifuged (500×g, 3 min, room temperature). The supernatant was aspirated, 2 ml of PBS was added, and the medium was washed. The supernatant was further aspirated, 2 ml of Accumax (Innovative Cell Technologies) was added, and the pellet was tapped and left to stand for 20 min to obtain single floating cells. The spheroids were added to the washing medium, centrifuged (500×g, 3 min, room temperature), and the supernatant was removed by aspirating. After adding 2 ml of PBS, 100 μL was dispensed and pipetted into 100 μL of 0.5% trypan blue staining solution. After mixing by pipetting several times, the trypan blue stained cell suspension was placed on a hemocytometer and the number of blue-stained dead cells and unstained live cells was counted.

[0172] <Evaluation criteria> The percent cell viability was calculated using the following formula: (% Viability) = (number of unstained cells) / (total number of unstained and blue stained cells) ◎: Survival rate % ≥ 50% (particularly good) ○:50%>survival rate%≧40% (good) △:40%>survival rate%≧20% (acceptable) ×:20%>Survival rate% (defective) The evaluation results are shown in Table 9.

[0173] <Evaluation of spheroid proliferation after reseeding> Using cell freezing storage solutions 1 to 22, all cultures were dissociated with 0.25% Trysin-EDTA at 37°C for 3 minutes, washed twice with MEMα medium, and centrifuged at 300g for 5 minutes at 4°C to recover spheroids and single cells. The initial cell number for seeding was adjusted to 5 × 104 cells / well in MEMα. The cells were seeded in a 24-well flat-bottom culture well (made of polystyrene, with an adhesion-treated culture surface) manufactured by PP Co., Ltd. On the sixth day after culture, the adhesion and spreading state of the spheroid edges were observed to evaluate the confluence of the cells. - Evaluation criteria for cell proliferation of spheroids upon reseeding ◎: No spheroids were observed in the field of view, cell adhesion and spreading were observed, and the cells were confluent. Cell proliferation was excellent. ○: No spheroids were observed in the field of view, and cell adhesion and spreading were observed, but the cells were not confluent. Cell proliferation was good. △: One or more spheroids with a diameter of 200 μm or less (including 200 μm) are observed remaining on the culture surface in the field of view. Cell proliferation is somewhat good. ×: One or more spheroids with a diameter of 200 μm or more are observed remaining on the culture surface in the field of view. Cell proliferation is poor.

[0174] <Evaluation of undifferentiated spheroids - quantitative real-time PCR (qRT-PCR)> For the cells used in the proliferation evaluation, total RNA was extracted from the cultures after 3 days of culture with TRIzol reagent (Invitrogen Corporation, Carlsbad, CA. USA), and cDNA was synthesized with PrimeScriptTMRT MasterMix (PerfectRealTime) (Takara, Cat#RR036A) according to the manufacturer's protocol. qRT-PCR was performed in triplicate using TBGreen PremixExTaqII (Takara, RR820A) with a Thermal Cycler Dice RealTime System (Takara TP900). The volume for qRT-PCR was 25 μL, containing 1 μL (μg) cDNA, 12.5 μL TBGreen Premix ExTaqII (Takara, RR820A), 1 μL each of specific forward and reverse primers, and 9.5 μL sterile water.

[0175] qRT-PCR was performed at 95°C for 30 s, followed by 40 cycles of 95°C for 5 s and 60°C for 30 s, followed by 95°C for 15 s, 60°C for 30 s, and 95°C for 15 s. Data were analyzed by ΔΔCt ratio quantification. Data were normalized to GAPDH levels and compared to control values.

[0176] The sequences of the primers used are as follows: SSEA1 (also known as Fut4) Forward primer: GCAGGGCCCAAGATTAACTGAC (SEQ ID NO: 1) Reverse primer: AAGCGCCTGGGCCTAAGAA (SEQ ID NO: 2) Sox2 Forward primer: GTTCTAGTGGTACGTTAGGCGCTTC (sequence no. No. 3) Reverse primer: TCGCCGGAGTCTAGGCTAAATA (SEQ ID NO: 4) Nanog Forward primer: TGCCTCACACGGAGACTGTC (SEQ ID NO: 5) Reverse primer: AGTGGGTTGTTTGCCTTTGG (SEQ ID NO: 6) Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) (as an internal positive control)

[0177] [Statistical analysis] Data were analyzed by one-way analysis of variance (ANOVA). In case of significant F ratios, Tukey's post hoc test was performed. The significance level was set at P<0.05, and the results are presented as mean±SD unless otherwise indicated. All data are from at least three independent experiments unless otherwise indicated.

[0178] Evaluation criteria for gene expression [SSEA1, Sox2, Nanog] ◎: gene expression level ≦2; gene expression level is quite high. ○: 1.5≦gene expression level<2; gene expression level is high. △: 1≦gene expression level<1.5; gene expression level is slightly high. ×: gene expression level < 1; gene expression level is low.

[0179] [Table 9]

[0180] From the above, it was demonstrated that the use of the cell cryopreservation solution of the present invention results in good cell survival rate, proliferation rate, and undifferentiated state after thawing.

[0181] This is believed to be because the amino acid polymer contained in the cell cryopreservation solution of the present invention contains a large amount of unfrozen water that strongly interacts with nearby water and does not form hydrogen bonds like ordinary water during the freezing process, thereby avoiding physical damage caused by ice crystal growth during freezing and ensuring cell survival and proliferation rates after thawing. In addition, the presence of non-frozen water in the cell cryoprotectant maintains a stable hydration state outside the cell membrane and makes it possible to control the rate at which low molecular weight solvents penetrate into the membrane. This is thought to be because, during the spheroid freezing process, the time difference in freezing between the inside and periphery of the spheroid is mitigated, thereby ensuring the survival rate of the spheroid after thawing. In contrast, Comparative Examples 4-1 to 4-6 are cell cryopreservation solutions that do not contain an amino acid-based copolymer, and it is believed that cryopreservation of spheroids was not possible.

Claims

1. A protein stabilizer or blocking agent comprising an amino acid-based polymer (A) having an amino acid residue-containing structural unit, wherein the amino acid-based polymer (A) is obtained by copolymerization of monomers including at least any one of monomers (a1) to (a3) ​​having amino acid residue structures represented by the following general formulas (4) to (6): Monomer (a1) 【Chemistry 1】 ...General formula (4) Monomer (a2) 【Chemistry 2】 ...General formula (5) Monomer (a3) 【Chemistry 3】 ...General formula (6) (In the general formulas (4) to (6), A represents an amino acid residue, X and Y each independently represent O or NH, R1 represents an alkylene group, R2 represents an alkylene group, an alkylene group in which one or more hydrogen atoms are substituted with hydroxyl groups, a phenylene group, an ester group, an ether group, a urethane bond, an amide bond, or a nonionic divalent group consisting of a combination thereof, and R3 represents H or CH 3 .) However, this does not include the case where the amino acid polymer (A) is the following [1] or [2]: [1] A polymer obtained by copolymerizing at least a monomer represented by the following general formula (7) and a monomer represented by the following general formula (8): 【Chemistry 4】 ...General formula (7) (In general formula (7), R 11 represents a hydrogen atom or a methyl group, and R 12 represents a single bond or a linear or branched alkylene group having 1 to 5 carbon atoms.) 【Chemistry 5】 ...General formula (8) (In general formula (8), R 13 represents a hydrogen atom or a methyl group, and R 14 represents a hydrogen atom, a linear, branched or cyclic alkyl group, alkoxyl group or alkylamino group having 1 to 10 carbon atoms, an aryl group, or a heterocyclic group.) [2] A polymer comprising one or more repeating units of the following general formula (9) and one or more repeating units of the following general formula (10): 【Chemistry 6】 ...General formula (9) 【Chemistry 7】 ...General formula (10) (In the general formulas (9) and (10), X (which may be the same or different in the repeating unit of the general formula (9)) and Y (which may be the same or different in the repeating unit of the general formula (10)) are hydrocarbon residues which provide the main chain of the polymer and are optionally substituted; R 1 (which may be the same or different in the same repeat unit of formula (10) or in different repeat units of formula (10) when n or q is 2 or more) is hydrogen or a methyl group; R 2 (which may be the same or different in the same repeat unit of formula (10) or in different repeat units of formula (10) when n or q is 2 or more) is hydrogen or a methyl group; provided that R 1 and R 2 in a single unit CHR 1 CHR 2 O cannot both be a methyl group at the same time; R 3 (which may be the same or different in the same repeat unit of formula (10) or in different repeat units of formula (10) when q is 2 or more) is hydrogen, or a lower alkyl group containing up to 5 carbon atoms, or an acyl group derived from an alkanoic acid containing up to 5 carbon atoms; n is a number from 1 to 10; p is a number from 1 to 4; q is a number from 1 to 4; Each CO 2 H group is bonded to a hydrocarbon residue X via one or more intermediate bonds L, and when p is 2 to 4, may be bonded by L to the same or different carbon atoms of X; L represents one or more intermediate bonds, and L may be the same or different in the repeat unit of formula (9) and is selected from one or more direct bonds, and one or more atomic groups each providing a chain of one or more atoms to connect the CO2H groups to X, with the proviso that not more than two CO2H groups can be directly bonded to the same carbon atom in X; Each (CHR 1 CHR 2 O) n group is bonded to a hydrocarbon residue Y via one or more intermediate bonds M, and when q is 2 to 4, may be bonded by M to the same or different carbon atoms of Y; M represents one or more intermediate bonds, and M may be the same or different in the repeat unit of formula (10) and is selected from one or more direct bonds, and one or more atomic groups each providing a chain of one or more atoms to connect the (CHR 1 CHR 2 O) n groups to Y, with the proviso that not more than two CHR 1 CHR 2 O groups can be directly attached to the same carbon atom in Y; The ratio of --(number of CO 2 H groups):(number of --CHR 1 CHR 2 O-- groups) is in the range of 1:20 to 20:

1.

2. 2. The protein stabilizing agent or blocking agent according to claim 1, wherein the amino acid polymer (A) has a mass average molecular weight of 2,000 or more.

3. 2. The protein stabilizing agent or blocking agent according to claim 1, wherein the amount of nonfreezing water (water that does not freeze even at temperatures of -100°C or lower) measured in an aqueous solution having a concentration of 20.0 w / v % of an amino acid polymer (A) is 200 mg or more per 1 g of the polymer (A). The amount of unfreezable water is measured by the following method. Apparatus: Differential scanning calorimeter (DSC apparatus; Hitachi High-Tech Science DSC6200) Measurement conditions: nitrogen flow rate 50 mL / min, temperature rise rate 5° C. / min Temperature program: (i) cooling from room temperature to -100°C, (ii) holding at -100°C for 5 minutes, (iii) heating from -100°C to 30°C. Measurement method: The amounts of heat absorbed and released during the above process (iii) were measured. After the DSC measurement, each sample was vacuum-dried in an aluminum pan with a pinhole, and then the weight was measured. The weight loss was recorded as the water content. For each sample, the amount of free water not bound by the polymer was determined from the endothermic heat near 0°C, and the amount of intermediate water was determined from the amount of heat generated near -40°C and the endothermic heat at freezing points of -20°C or above. The amount of nonfreezable water was determined by subtracting the amounts of free water and intermediate water from the water content of each sample determined above (W1-W0) (W0: dry weight of sample (g), W1: water-containing weight of sample (g)). The amount of nonfreezable water per 1 g of amino acid polymer (A) was determined by dividing the determined amount of nonfreezable water by the dry weight of the sample (W0).

4. 2. The protein stabilizing agent or blocking agent according to claim 1, wherein the amino acid-based polymer (A) contains 30 to 100% by mass of at least any one of structural units derived from monomers (a1) to (a3) ​​having amino acid residue structures represented by general formulas (4) to (6), relative to 100% by mass of the total of structural units constituting the amino acid-based polymer (A).

5. 2. The protein stabilizing agent or blocking agent according to claim 1, wherein the concentration of the amino acid polymer (A) is 0.01 to 30.0 w / v %.

6. A method for stabilizing a protein, comprising coexisting the protein with the protein stabilizer or blocking agent described in any one of claims 1 to 5.

7. An immunoassay method comprising the step of treating a carrier containing an antigen or antibody with the protein stabilizing agent or blocking agent according to any one of claims 1 to 5.

8. The immunoassay method according to claim 7 , wherein the carrier is latex particles, an ELISA plate, an immunochromatographic membrane, or a gold colloid.

9. A carrier containing an antigen or antibody against a target substance, partially or completely coated with a protein stabilizer or blocking agent described in any one of claims 1 to 5.

10. A kit for immunoassay comprising the carrier according to claim 9.

Images